GALDERMA LABORATORIES, L.P.  Page 1 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 Title: A Prospective, Open-Label, Multicenter Study to Evaluate the Long-
Term Safety of Sculptra®Aesthetic in Immuno-Competent Subjects 
Stratified by Fitzpatrick Skin Type I-VI 
Protocol number: GLI.04.SPR.US10321 
Study phase: 4 
Sponsor name and 
address: Galderma Laboratories, L.P. (GLLP) 
14501 North Freeway 
Fort Worth, TX 76177 
Study 
products: Sculptra® Aesthetic (injectable poly-L-lactic acid)  
Indication: Use in immune-competent subjects for the correction of shallow to deep 
nasolabial fold contour deficiencies and other facial wrinkles in which 
deep dermal grid pattern (cross-hatch)  injection technique is appropriate 
Investigator agreement: I have examined the above-referenc ed Galderma Laboratories, L.P. 
clinical trial protocol and have fully discussed the objectives of this 
clinical trial and the content of this clinical trial protocol with the 
Sponsor’s team, recognize its confidentiality, and agree to conduct the 
described trial in compliance with Good Clinical Practices (GCP), the 
ethical principles contained within the Declaration of Helsinki, this 
protocol, and all applicable regulatory requirements. 
Principal 
Investigator:  
 
S i g n a t u r e      D a t e  
Name:  
Address:  
GALDERMA LABORATORIES, L.P.  Page 2 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 Title Page 
Title: A Prospective, Open-Label, Multicenter Study to Evaluate the Long-
Term Safety of Sculptra®Aesthetic in Immuno-Competent Subjects 
Stratified by Fitzpatrick Skin Type I-VI) 
Short Title:  Sculptra® Aesthetic Post-Approval Study 
Protocol number: GLI.04.SPR.US10321 
Study phase: 4 
IND/IDE Number N/A  
Sponsor: Galderma Laboratories, L.P. (GLLP) 
14501 North Freeway Fort Worth, TX 76177  
For any medical questions related to the protocol please contact the Study Medical Monitor: 
This study  will be performed in com p
liance with a pplicable federal regulations and Good Clinical 
Practice (GCP). This Clinical Study Protocol follows guidelines outlined by the International Conference 
on Harmonization (ICH), the ethical principles contained within the Declaration of Helsinki, and all 
applicable regulatory requirements.     
All the data provided to the investigator and his/ her staff and all data obt ained through this GLLP 
protocol will be regarded as confidential and proprietary in nature and should not be disclosed to any third 
party without GLLP’s written consent. 
Effective Date:  24 April 2015 
  
PPD
GALDERMA LABORATORIES, L.P.  Page 3 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 Protocol Amendment 1 
Purpose: A change is being made to protocol GLI.04.SPR.US10321 dated 7 January 2015 to 
address Institutional Review Board comments as follows: 
 Clarification to the requirement to conduct a urine pregnancy test prior to 
treatment with study product. 
 Clarification to the oral/systemic contraceptive requirement 
 
Rational :  Requested by IRB 
 
Current study status :  No sites have been initiated at time of this amendment. 
 
Electronic Case Report Form revision required :  No 
 
Informed Consent modification required:  Yes 
 
Applicable Investigators : All  
 Itemized Changes : See table below
GALDERMA LABORATORIES, L.P.  Page 4 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
Protocol Section 
Protocol Page # Reason for Change Original Protocol Language Updated Protocol Language  
(changes in bold font) 
Protocol Synopsis, 
Exclusion criteria #16 
Page 12 and 31 Typographical error 
(changed to be consistent with Section 13.3.2.2) Pregnancy status should be checked by urine testing at Visit 1. Pregnancy status must  be checked by 
urine testing at Visit 1. 
Protocol Synopsis, Exclusion criteria #16 
Page 12 and 31 Clarification of 
oral/systemic 
contraceptive 
requirement Effective birth control is defined as follows: (1) have had a hysterectomy or tubal ligation; or (2) 
use oral/systemic contraceptives; (3) use an 
intrauterine device; or (4) use double-barrier (eg, condom and spermicidal foam, gel or insert or condom and diaphragm); or (5) use implants or injectables, for at least 28 days prior to the start of 
the study; or (6) be post- menopausal for at least 1 
year prior to entry into the study. Birth control regimen must be maintained throughout the study. Effective birth control is defined as follows: (1) have had a hysterectomy or 
tubal ligation; or (2) use oral/systemic 
contraceptives for at least 3 months 
prior to the start of the study ; or (3) use 
an intrauterine device; or (4) use double-barrier (eg, condom and spermicidal 
foam, gel or insert or condom and 
diaphragm); or (5) use implants or injectables, for at least 28 days prior to the start of the study; or (6) be post- menopausal for at least 1 year prior to entry into the study. Birth control regimen 
must be maintained throughout the study. 
Protocol Synopsis, Study Design 
Page 10 Typographical error 
(changed to be 
consistent with p. 12) This is a prospective, open-label; multicenter (at 
up to 20 sites) US study…. This is a prospective, open-label; multicenter (at a minimum of  20 sites) 
US study…. 
 
CCI
GALDERMA LABORATORIES, L.P.  Page 5 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 Table of Contents 
 
1  SYNOPSIS  ...........................................................................................................................................  9 
2   FLOW CHART OF STUDY PROCEDURES  ............................................................................................  19 
3  LIST OF ABBREVIATIONS  ..................................................................................................................  22 
4  INTRODUCTION  AND RATIONALE  ....................................................................................................  23 
5  STUDY OBJECTIVES  ..........................................................................................................................  28 
5.1 PRIMARY  ......................................................................................................................................  28 
5.2 SECONDARY  .................................................................................................................................  28 
6  STUDY DESIGN .................................................................................................................................  28 
6.1 DESCRIPTION  OF THE PROTOCOL ................................................................................................  28 
6.2 DUR
ATION OF STUDY  ..................................................................................................................  29 
6.3 INTERIM  ANALYSIS  ......................................................................................................................  29 
7  SELECTION  OF SUBJECTS  ..................................................................................................................  29 
7.1 NUMBER OF SUBJECTS  PLANNED  ...............................................................................................  29 
7.2 INCLUSION  CRITERIA  ...................................................................................................................  29 
7.3 EXCLUSION  CRITERIA  ..................................................................................................................  30 
8  TREATMENTS  ...................................................................................................................................  32 
8.1 INVESTIGATIONAL  PRODUCT  .......................................................................................................  32 
8.2 COMPENSATION  FOR LACK OF BLINDI NG ...................................................................................  33  
8.3 METHOD OF ASSIGNING  SUBJECTS  TO TREATMENT  GROUP  .....................................................  33 
8.4 PACKAGING  AND LABELING  ........................................................................................................  34 
8.5 STORAGE  CONDITIONS  ................................................................................................................  34 
8.6 RESPONSIBILITIES  ........................................................................................................................  34 
8.7 RETRIEVAL  AND/OR DESTRUCTION  OF INVESTIGATIONAL  PRODUCT  .........................................  35 
8.7.1   Partially used  or unused treatment  .........................................................................................  35 
8.7.2   Potential recall .........................................................................................................................  35 
8.8 CONCOM I
TANT TREATMENT  ......................................................................................................  35 
8.9 POST‐STUDY TREATMENT  ...........................................................................................................  37 
8.10  TREATMENT  ACCOUNTABILITY  AND COMPLIANCE  .....................................................................  37 
8.11  PRODUCT  TECHNICAL  COMPLAINTS  ...........................................................................................  37 
9  ASSESSMENT  OF THE INVESTIGATIONAL  PRODUCT  ........................................................................  37 
9.1 SAFETY .........................................................................................................................................  37 
9.1.1 Primary  safety criteria ................................................................................................................  37 
9.1.2 Secondary  safety criteria ...........................................................................................................  38 
GALDERMA LABORATORIES, L.P.  Page 6 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 9.2 EFFICACY  .....................................................................................................................................  38 
9.2.1 Wrinkle assessments  ..................................................................................................................  38 
9.2.1.1 Nasolabial  fold assessments  and measurements  ...............................................................  38 
9.2.1.2 Other facial wrinkle assessments  and measurements........................................................  39 
9.2.2 Investigator  global evaluation  ...................................................................................................  40 
9.2.3 Subject global evaluation  ...........................................................................................................  40 
10  SUBJECT SAFETY ...............................................................................................................................  41 
10.1 ADVERSE EVENTS MONITORING  .................................................................................................  41 
10.2 DEFINITIONS  OF ADVERSE EVEN T S AND SERIOUS ADVERSE EVENT ...........................................  41 
10.3 SEVERITY  OF ADVERSE EVENTS ...................................................................................................  41 
10.4 RELATEDNESS  OF ADVERSE EVENT (AE) ......................................................................................  42 
10.5 OBLIGATION  OF THE INVESTIGATOR  REGARDING  SAFETY REPORTING  ......................................  42 
10.6 ADVERSE EVENTS AS PRODUCT  TECHNICAL  COMPLAINTS  .........................................................  44 
10.7 PREGNANCY  ............................................................................................................................... . 44 
11  HANDLING  OF SUBJECT TEMPORARY  OR DEFI NITIVE TREATMENT  DISCONTINUATION  AND OF 
SUBJECT STUDY DISCONTINUATION  ................................................................................................  44 
11.1 TEMPORARY  TREATMENT  DISCONTINUATION  WITH INVESTIGATIONAL  PRODUCT  ..................  44 
11.2 DEFINITIVE  TREATMENT  DISCONTINUATION  WITH INVESTIGATIONAL  PRODUCT  ....................  45 
11.2.1 Criteria for definitive  treatment  discontinuation  with investigational  product ......................  45 
11.2.2 Handling of subjects after definitive  treatment  discontinuation  ............................................  45 
11.3 PROCEDURE  FOR WIT
HDRAWAL  OF SUBJECTS  FROM STUDY FOLLOW‐UP SCHEDULE  ............. 46 
11.4 CONSEQUENCE............................................................................................................................  46 
12  STUDY PROCEDURES  ........................................................................................................................  46 
12.1 VISIT SCHEDULE  ...........................................................................................................................  46 
12.1.1 Visit 1 (Day 1) – Screening/initial  treatment  ............................................................................  46 
12.1.2 Visit 2 (Week 3) – second treatment,  if needed ......................................................................  48 
12.1.3 Visit 3 (Week 6) – thir d treatment,  if needed ..........................................................................  49 
12.1.4 Visit 4 (Week 9) – fourth treatment,  if needed ........................................................................  51 
12.1.5 Follow‐up phase .......................................................................................................................  53 
12.1.5.1 Follow‐up visits at Month 3, 6, 9, and 13 ..........................................................................  53 
12.1.5.2 Follow‐up visits at Years 2, 3, and 4 ..................................................................................  55 
12.1.5. 3 En
d of study or early termination  visit  (Year 5) ................................................................  56 
12.2 MONTHLY  SAFETY CONTACTS  .....................................................................................................  57 
12.3 UNSCHEDULED  VISITS .................................................................................................................  57 
GALDERMA LABORATORIES, L.P.  Page 7 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 12.4 EARLY TERMINATION  ..................................................................................................................  58 
12.5 DEFINITION  OF SOURCE DATA ....................................................................................................  58 
13  STATISTICAL  CONSIDERATIONS  .......................................................................................................  58 
13.1 STATISTICAL  AND ANALYTICAL  PLANS .........................................................................................  58 
13.3 ANALYSIS  VARIABLES  ...................................................................................................................  59 
13.3.1 Demographic  and baseline characteristics  ..............................................................................  59 
13.3.2 Safety variables ........................................................................................................................  59 
13.3.2.1 Adverse events ..................................................................................................................  59 
13.3.2 .2 Laboratory  safe
ty variables ...............................................................................................  60 
13.3.2.3 Vital signs and physical exam ............................................................................................  60 
13.3.2.4 Other safety variables .......................................................................................................  60 
13.3.3 Efficacy variables ......................................................................................................................  60 
13.3.3.1 Primary  efficacy variables .................................................................................................  60 
13.3.3.2 Secondary  efficacy  variables .............................................................................................  60 
13.4 ANALYSIS  POPULATIONS  .............................................................................................................  60 
13.4.1 Efficacy populations  .................................................................................................................  61 
13.4.2 Safety populatio ns ...................................................................................................................  61  
13.4.3 Other analysis populations  ......................................................................................................  61 
13.4.4 Disposition  of subjects .............................................................................................................  61 
13.5 STATISTICAL  METHODS  ...............................................................................................................  61 
13.5.1 Demographics  and baseline characteristics  .............................................................................  61 
13.5.2 Extent of study treatment  exposure  and compliance  .............................................................  62 
13.5.3 Analysis of efficacy variables....................................................................................................  62 
13.5.4 Analysis of safety data .............................................................................................................  62 
 
13.5.4 .2 Othe r ana
lyses of adverse events .....................................................................................  64 
13.5.4.3 Laboratory  variables analysis ............................................................................................  65 
13.5.4.4 Analysis of vital sign variables ...........................................................................................  65 
13.5.4.5 Analysis of other safety variables .....................................................................................  65 
13.5.4.6 Analysis of pharmacokinetic  and pharmacodynamic  variables ........................................  65 
13.5.4.7 Analysis of health economics  variables ............................................................................  65 
13.6 IN
TERIM ANALYSIS  ......................................................................................................................  65 
CCI
CCI
GALDERMA LABORATORIES, L.P.  Page 8 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 13.7 MISSING DATA ............................................................................................................................  66 
14  ETHICAL AND REGULATORY  STANDARDS  ........................................................................................  66 
14.1 ETHICAL PRINCIPLES  ....................................................................................................................  66 
14.2 LAWS AND REGULATIONS  ...........................................................................................................  66 
14.3 INFORMED  CONSENT  ..................................................................................................................  66 
14.4 INSTITUTIONAL  REVIEW BOARD (IRB)  .........................................................................................  67 
15  STUDY MONITORING  .......................................................................................................................  67 
15.1 RESPONSIBILITIES  OF THE INVESTIGATOR(S)  ..............................................................................  67 
15.2 RESPONSIBILITIES  OF THE SPONSOR  ...........................................................................................  69 
15.3 SO
URCE DOCUMENT  REQUIREMENTS  ........................................................................................  69 
15.4 USE AND COMPLETION  OF CASE REPORT FORMS AND ADDITIONAL  REQUEST  .........................  69 
15.5 USE OF COMPUTERIZED  SYSTEMS ..............................................................................................  70 
16  ADMINISTRATIVE  RULES ..................................................................................................................  70 
16.1 CURRICULUM  VITAE ....................................................................................................................  70 
16.2 RECORD RETENTION  IN STUDY SITE(S) .......................................................................................  70 
17  CONFIDENTIALITY  ............................................................................................................................  70 
18  PROPER TY RI
GHTS ...........................................................................................................................  71 
19  DATA PROTECTION  ..........................................................................................................................  71 
20  SPONSOR  AUDITS AND INSPECTIONS  BY REGULATORY  AGENCIES  .................................................  72 
21  PREMATURE  DISCONTINUATION  OF THE STUDY OR PREMATURE  CLOSE‐OUT OF A SITE .............. 72 
21.1 DECIDED BY THE SPONSOR  IN THE FOLLOWING  CASES ..............................................................  72 
21.2 DECIDED BY THE INVESTIGATOR  .................................................................................................  73 
22
  CLINICAL TRIAL RESULTS ..................................................................................................................  73 
23  PUBLICATIONS  AND COMMUNICATIONS  ........................................................................................  73 
23.1 PUBLICATION/COMMUNICATION  OF STUDY RESULTS ...............................................................  73 
23.2 PUBLIC DISCLOSURE  OF CLINICAL TRIALS ...................................................................................  74 
24  CLINICAL TRIAL PROTOCOL  AMENDMENTS  ....................................................................................  75 
25  BIBLIOGRAPHIC  REFERENCES  ..........................................................................................................  76 
26   APPENDICES  ....................................................................................................................................  78 
APPENDIX  I – FITZPATRICK  SKIN TYPE .........................................................................................................  79 
APPENDIX  II ‐ NASOLABIAL  FOLD WRINKLE  ASSESSMENT  SCALE ................................................................  80 
APPENDIX  III – ASSESSMENT  SCALE FOR OTHER FACIAL WRINKLES  ...........................................................  81 
APPENDIX  IV – AMERICAN  SOCIETY OF .......................................................................................................  84 
ANESTHESIOLOGISTS’  PHYSICAL  STATUS CLASSIFICATION  SYSTEM  ...........................................................  84 
 
  
GALDERMA LABORATORIES, L.P.  Page 9 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 1 SYNOPSIS 
 
 
Compound:  
Sculptra® Aesthetic 
Poly-L-lactic acid  
STUDY CODE:   
 GLI.04.SPR.US10321 
 
Title  
A Prospective, Open-Label, Multicenter Study to Evaluate the Long-
Term Safety of Sculptra® Aesthetic in Immuno-Competent Subjects 
Stratified by Fitzpatrick Skin Type I-VI 
 
 
Trial Location  
United States 
 
 
Sponsor Medical 
Director 
Galderma Laboratories, LP 
 
  
Study Objectives  
The primary objective of the study is to assess the long-term safety of 
Sculptra® Aesthetic (injectable poly-L-lactic acid [PLLA]) in immune- competent subjects as a single regimen for correction of wrinkle assessment score (WAS) 2 to 4 nasolabial fold (NLF) contour 
deficiencies and other facial wrinkles in which deep dermal grid pattern 
(cross-hatch) injection technique is appropriate, for the following variables: 
 The device-related long-term incidence of chronic inflammation 
(nodules, papules, granulomas, skin necrosis, hypersensitivity, and 
other injection site reactions) in subjects with Fitzpatrick skin type 
I-VI. 
 The incidence of hypertrophic scarring, keloid formation, and 
changes in skin pigmentation in subjects with Fitzpatrick skin type 
IV-VI. 
 
Secondary objectives include the following: 
 To evaluate the time to onset, duration, severity, relationship to 
Sculptra® Aesthetic (injectable PLLA) and/or injection procedure, and 
outcome of all adverse events, including adverse events mentioned 
under the primary objectives, during the course of the study, by 
Fitzpatrick skin type. 
 To evaluate the change in the WAS from baseline to post treatment follow- up time points at Months 6, 13, and Years 2, 3, 4, and 5 in 
NLFs and other facial wrinkles. 
 To evaluate Investigator/subject global assessments at Months 6, 13, 
and Years 2, 3, 4, and 5. 
 
 
 
PPD
GALDERMA LABORATORIES, L.P.  Page 10 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
Study Design  
This is a prospective, open-label; multicenter (at a minimum of 20 sites) US 
study to evaluate the long-term safety of Sculptra® Aesthetic (injectable 
PLLA) in immuno-competent subjects, stratified by Fitzpatrick skin type18 
I-III, IV, and V-VI (see Appendix I ). 
 
 
Study Population  
Immuno-competent male or female subjects 18 to 75 years of age with 
NLF contour deficiencies and other facial wrinkles as defined by WAS criteria. 
 
 
Main selection criteria   
Inclusion criteria  
In order to be eligible to enter into the study, subjects must fulfill 
all of the following inclusion criteria: 
1. Subjects seeking correction of shallow to deep NLF contour 
deficiencies. Subjects must have a score of ≥2 and ≤4 on the 
photo-numeric wrinkle assessment scale of both the right and left 
NLFs at entry (see Appendix II ). 
 Subjects may also have other facial wrinkles (ie, cheek lines, 
marionette lines, and chin crease/chin fold) using the Assessment 
Scale for Other Facial Wrinkles (see Appendix III ) for which deep 
dermal grid pattern (cross-hatch) injection technique is appropriate. 
2. Subjects must sign a statement of informed consent including full 
copyright release of photographs to the Sponsor; initial and date “A 
Patient’s Guide to Treatment with Sculptra® Aesthetic”; and Health 
Insurance Portability and Accountability Act (HIPAA) authorization. 
 
Exclusion criteria   
Subject will not be enrolled in the study if any of the following 
exclusion criteria are present/met: 
1. Subjects seeking, at entry into the study, correction of other facial 
wrinkles with Sculptra® Aesthetic in the following anatomical 
sites/lines: horizontal forehead lines, glabellar frown lines, 
periorbital lines, periauricular lines, upper lip lines, lower lip lines, 
corner of the mouth lines and/or horizontal neck folds. 
2. Subjects that are less than 18 or greater than 75 years of age. 
3. Subjects with a score of 0, 1, or 5 on the photo-numeric wrinkle 
assessment scale of either the right or left NLFs (see Appendix II ). 
4. Personal history of allergic/anaphylactic reactions including 
hypersensitivity to local anesthetics (eg, lidocaine, etc), latex, or any 
of the Sculptra® Aesthetic constituents. 
5. History of facial skin cancer or recurrence of facial skin cancer 
other than basal cell carcinoma within 5 years. 
6. Known history of keloids or bleeding/coagulation disorder. 
GALDERMA LABORATORIES, L.P.  Page 11 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 7. History of human immunodeficiency virus, diabetes, connective 
tissue disorders (eg, lupus, scleroderma), or other serious 
systemic disease (eg, sarcoidosis). 
8. Presence of surgical or non-surgical scars in the area to be 
treated. 
9. Active inflammatory process or infection in the area to be 
treated (skin eruptions such as cysts, pimples, rashes, herpes 
simplex, herpes zoster, cancerous/precancerous lesions), or any 
other active or serious skin disease (eg, eczema, psoriasis of the face, severe rosacea, severe acne, etc.). 
10. Subjects with an American Society of Anesthesiologists’ 
Physical Status Classification System Score of ≥P3 (P3 = a 
subject with severe systemic disease) (see Appendix IV ). 
11.  Subjects with medical conditions that might require the use of 
immunosuppressive (except for oral steroids that can be used for 
less than 1 month over the duration of the study) or anti-
inflammatory medications during the trial (eg, severe asthma, rheumatoid arthritis, etc). 
12.  Viral, chemical, or any active hepatitis within the past year. 
13.  Planned surgical procedures with incisions and suturing in the 
area to be treated during the course of the study. 
14. Planned major facial aesthetic procedure/plastic surgery (eg, 
rhinoplasty [with or without implant], facelift, congenital defect 
repair, etc) during the course of the study. 
15. Subjects who have or plan to use exclusionary treatments/medications/  devices, as described 
below ( or who are unable to comply with 
concomitant therapy restrictions as described in Section 8.8): 
a. Cosmetic permanent filler-type injectable products (eg, poly 
methylmethacrylate [PMMA], etc.) in the facial treatment 
area at any time prior to or during the study. 
b. Immunosuppressive medications including systemic steroids (eg, 
oral prednisone) within 6 months of treatment or for more than 1 month of treatment over the duration of the study. 
Intranasal/inhaled or topical steroids are acceptable. 
c. Previous injectable PLLA treatment in the face. 
d. Temporary dermal fillers within 18 months of treatment in the 
same area to be treated with Sculptra® Aesthetic. 
e. Botulinum toxin (any Type) within 6 months of treatment 
in the same area to be treated with Sculptra® Aesthetic. 
f. Subjects receiving antiplatelet (eg, full strength aspirin [> 81 
mg/per day], high dose aspirin-containing products, clopidogrel, 
etc.); anticoagulant (eg, coumarin derivatives, unfractionated heparin, low molecular weight heparin, selective factor Xa inhibitor, thrombin inhibitor, etc.) or non- steroidal anti-inflammatory agents; in whom, in the Investigator’s opinion, administration of Sculptra® Aesthetic may cause procedure-
related co mplications a tthe in jection site.
GALDERMA LABORATORIES, L.P.  Page 12 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 g. Prescription facial wrinkle therapies that include retinoic acid 
derivatives, prescription strength alpha-hydroxyacids and beta-
hydroxyacids and idebenone 1% in the area to be treated less than 3 months prior to enrollment. 
h.  Hand-held light therapy devices for personal use such as LED or 
laser resurfacing, intense light pulse therapy or radiofrequency in 
the area to be treated less than 6 months prior to enrollment. 
16.  Women who are pregnant, nursing or intend to become pregnant 
over the duration of the study or women who are of childbearing potential not protected by effective contraceptive method of birth 
control and/or who are unwilling or unable to be tested for pregnancy. Pregnancy status must be checked by urine testing at Visit 1. 
 Effective birth control is defined as follows: (1) have had a 
hysterectomy or tubal ligation; or (2) use oral/systemic contraceptives
 for at least 3 months prior to the start of the study; 
or (3) use an intrauterine device; or (4) use double-barrier (eg, condom and spermicidal foam, gel or insert or condom and diaphragm); or (5) use implants or injectables, for at least 28 days prior to the start of the study; or (6) be post- menopausal for at 
least 1 year prior to entry into the study. Birth control regimen 
must be maintained throughout the study. 
17.  Subjects who are unwilling or unable to give written consent to 
participate in the investigation or unable to comply with the requirements of the clinical trial protocol. 
18.  Subjects who have received any experimental drug or device 
within the previous 3 months prior to first treatment. 
19. Subjects who are known alcohol or drug abusers. 
20. Subjects who are suffering from any psychological condition, or are 
under treatment for any condition which, in the opinion of the 
Investigator and/or consulting physicians(s) may constitute an unwarranted risk or which may affect the subjects’ compliance or adherence to study procedures 
 
Note: No waiver, prospective or retrospective, to deviate in 
any way from the inclusion/exclusion criteria for clinical 
trial subjects, defined in the clinical trial protocol, can be 
granted to clinical Investigators.  
  
 
Total expected 
number of subjects  
Approximately 863 subjects to be enrolled and treated (with a planned 
minimum of 15 subjects per site) in order to have 604 evaluable subjects at the end of the study.  
 
Expected number of 
sites  
Minimum of 20 
 
GALDERMA LABORATORIES, L.P.  Page 13 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
 
 
Investigational 
Products  
Sculptra® Aesthetic (injectable poly-L-lactic acid) 
 
Formulation(s)  
Sterile freeze dried injectable implant. Reconstituted with 5 mL sterile water 
for injection (SWFI) at least 2 hours prior to use at each investigational site. 
 
 
Route(s) of 
administration  
Deep dermal injection into the nasolabial and other appropriate facial 
wrinkles where grid pattern technique is appropriate.  
 
Dose regimen  
Each subject will receive a single regimen of Sculptra® Aesthetic. A 
single regimen consists of up to 4 injection sessions with 3-week 
intervals, of multiple 0.1 to 0.2 mL deep dermal injections in a grid 
pattern, spaced at a distance of approximately 1 cm. A maximum of 5 mL per side of the face that includes up to 2.5 mL per NLF will be administered per injection session.  
 
Primary Endpoints 
 
Safety  
The co-primary safety endpoints are: 
 The percentage (incidence rate) of subjects with any injection site 
nodule  and/or papule over 5 years. 
 The percentage (incidence rate) of subjects with any of the following  
injection site events over 5 years: 
- Hypertrophic scarring 
- Keloid formation 
- Changes in the skin pigmentation at the site of injection 
compared to adjacent skin 
- Granuloma (confirmed by a biopsy) 
- Skin necrosis 
- Hypersensitivity reactions - Unexpected change in wrinkle contour 
The injection site adverse events listed above are defined as adverse events of interest in this study. 
 
 
Secondary Endpoints  
Safety 
   
 
Efficacy  
The secondary safety endpoints are: 
 The percentages (incidence rate) of subjects with any injection site 
nodule and/or papule; the percentage of subjects who experienced any adverse events of interest other than nodule or papule over 2 years; location and intervention for any adve rse events of interest; adverse 
event severity, duration, time to onset, relationship to Sculptra® 
Aesthetic and relationship to injection procedure during the course of 
the study. 
 
The efficacy endpoints are: 
GALDERMA LABORATORIES, L.P.  Page 14 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  Change from baseline to post-treatment follow-up time points in the 
WAS at Month 6, Month 13, and Years 2, 3, 4, and 5. 
 Investigator/Subject Global Assessments Scores at Month 6, Month 13, 
and Years 2, 3, 4, and 5. 
 
 
Assessment Schedule  
Screening visit/initial treatment – Visit 1 (Day 1)  
 
During this visit appropriate subjects will be screened and enrolled into 
the study based on the inclusion/exclusion criteria. The first treatment will be administered at this visit. Eligible subjects will receive bilateral injections of Sculptra® Aesthetic in the left and right NLF wrinkles 
(WAS 2 to 4) and, if present, other facial wrinkles for which deep 
dermal grid pattern (cross-hatch) injection technique is appropriate. 
 
Additional treatment phase (if needed) – Visits 2 to 4 (Week 3 to Week 9)  
 
The additional treatment phase will consist of one to three additional visits (as determined by each Investigator) at three-week intervals during which subjects may receive bilateral injections of Sculptra® 
Aesthetic. Only NLFs and other facial wrinkles treated at Visit 1 may 
be treated at these visits. 
 
Follow-up phase – Visits 5 to 12 (Month 3 to Year 5) 
 Following the initial treatment visit, subjects’ safety will be evaluated at each visit. Investigator and subject assessment of effectiveness will be evaluated only at Months 6 and 13, and then at Years 2, 3, 4, and 5.  
 
Statistical Considerations  
Study population  
 
The intent-to-treat (ITT) population, per protocol (PP) population, and 
Completer2 and Completer5 populations are defined as follows: 
 
The analysis populations for efficacy will be the ITT population that 
consists of all subjects who receive at least one Sculptra® Aesthetic 
injection; the PP population will consist of all subjects who receive at least one Sculptra® Aesthetic injection and are without any major protocol deviation. 
 
The analysis populations for safety will also include the ITT population and the PP population. The ITT population is the primary population for hypothesis testing.  
The Completer2 population consists of all subjects who receive at least one 
Sculptra® Aesthetic injection and finish the second year visit. 
 
The Completer5 population consists of all subjects who receive at least one 
Sculptra® Aesthetic injection and finish the fifth year visit. 
GALDERMA LABORATORIES, L.P.  Page 15 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 
CCI
GALDERMA LABORATORIES, L.P.  Page 16 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 
CCI
GALDERMA LABORATORIES, L.P.  Page 17 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 Inter
im analysis  
Interim analyses are planned following completion of all subjects’ Month 
13, Year 2, 3, and 4 follow-up visits. All safety and efficacy data up to the 
interim cut- off date will be cleaned, interim locked, analyzed and reported. 
Formal hypothesis testing will be performed at Year 2 and 5. The adjustment for type I error for the primary hypothesis is not necessary, 
since no change to the study such as early termination is planned after the 
interim analysis. 
 
Missing data  
The following rules will be applied to handle missing data in the safety 
analyses: 
• If a subject discontinues the study before 5 years, all his/her safety 
information  before discontinuation will be used in the safety analysis 
and no imputation of missing data between the date of 
discontinuation and the 5-year time point will be made. Sensitivity 
analyses for primary and secondary hypotheses will be conducted. 
• If the timing of an adverse event cannot be identified because of 
missing data and the subject is treated, the adverse event will be 
considered as a treatment- emergent adverse event (TEAE). 
• If the assessment of the intensity is missing, the most severe case 
will be assumed in the frequency tables of adverse event 
intensit y.
CCI
GALDERMA LABORATORIES, L.P.  Page 18 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 • If the assessment of the relationship to the Sculptra® Aesthetic or 
injection procedure is missing, a possible relationship to the 
Sculptra® Aesthetic will be assumed in the frequency tables of possibly related adverse events. 
 
Detailed plans for handling missing data will be contained in the 
statistical analysis plan. 
 
 
Duration of Study 
Period  
The study participation for each subject will be approximately 5 years in 
duration. Subjects will receive open-label treatment at their screening/ 
initial treatment visit (Visit 1, Day 1 – first injection session). Subjects 
will continue to receive open- label treatment for up to 9 weeks (Visit 2, Week 3 [second injection session]; Visit 3, Week 6 [third injection session]; and Visit 4, Week 9 [fourth injection session]) if needed and determined by the clinical trial Investigator. Subjects will continue with follow-up visits at Months 3, 6, 9, and 13, and Years 2, 3, 4, and 5.  
  
GALDERMA LABORATORIES, L.P.  Page 19 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
2  FLOW CHART OF STUDY PROCEDURES 
Table 1 - Flow Chart 1 – Over view of Study Procedures 
 
Study Phase: Screening/ 
Initial Tx Additional Treatment (if needed) 
(3 Week Intervals) Follow-Up 
(All times Relative to the INITIAL Treatment Visit, Day 1) 
   Time Point: 
 
Procedures Visit 1 
Screening/ 
Initial Tx Visit Visit 2 Visit 3 
if needed Visit 4 
if needed Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 Visit 12 End of 
Study or Early 
Termination 
 
Day 1 Week 3 
±3days Week 6 
±3days  Week 9 
±3days  Month 3 
±2 weeks  Month 6 
±2 weeks  Month 9 
±2 weeks  Month 13 
±2 weeks  Year 2 
±4 weeks  Year 3 
±4 weeks  Year 4 
±4 weeks  Year 5 
±4 weeks  
Obtain Written Informed Consent (Provide “A 
patient’s Guide to Treatment with Sculptra® Aesthetic”), HIPAA Authorization, and 
Photographic Consent             
Review inclusion/exclusion criteria             
Perform physical examination 1            
Review medical history and prior and 
concomitant medications/treatments             
Perform urine pregnancy test 2            
Assess NLF (WAS) and other facial wrinkles 
(WAS) requiring treatment (refer to flow chart 
2 for Visits 1 to 4)             
Measure the length of nasolabial folds and other facial wrinkles requiring treatment             
Assess Fitzpatrick Skin Type             
Standardized photography (refer to flow chart 
2 for Visits 1 to 4)             
Measure area of treatment grid  3 3 3         
Administer local anesthetic (if applicable) 3 3 3 3         
Administer Sculptra® Aesthetic  3 3 3         
Distribute Diary Card             
Adverse event assessment            
Collect Diary Card            
1 Sitting heart rate and blood pressure, height, weight.  
2 Females of childbearing potential only.  
3 If needed and as determined by the Investigator.  
4 This should be conducted at each visit and at each monthly safety contact. Any changes should be updated.
Tx = treatment; WAS = wrinkle assessment score  
  
CCI
GALDERMA LABORATORIES, L.P.  Page 20 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
Table 1 - Flow Chart 1 – Over view of Study Procedures  (cont’d)  
 
Study Phase: Screening/ 
Initial Tx Additional Treatment (if needed) 
(3 Week Intervals) Follow-Up 
(All times Relative to the INITIAL Treatment Visit, Day 1) 
   Time Point: 
 
Procedures Visit 1 
Screening/ 
Initial Tx Visit Visit 2 Visit 3 
if needed Visit 4 
if needed Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 Visit 12 End of 
Study or Early 
Termination 
 
Day 1 Week 3 
±3days Week 6 
±3days  Week 9 
±3days  Month 3 
±2 weeks  Month 6 
±2 weeks  Month 9 
±2 weeks  Month 13 
±2 weeks  Year 2 
±4 weeks  Year 3 
±4 weeks  Year 4 
±4 weeks  Year 5 
±4 weeks  
Review of concomitant medications/treatment            
Investigator Global Evaluation            
Subject Global Evaluation            
Schedule next clinic visit             
Schedule monthly safety contacts     Schedule monthly safety contacts  between each follow-up visit 
Review subject contact information 4             
1 Sitting heart rate and blood pressure, height, weight. 
2 Females of childbearing potential only. 
3 If needed and as determined by the Investigator. 
4 This should be conducted at each visit and at each monthly safety contact. Any changes should be updated. 
Tx = treatment; WAS = wrinkle assessment score  
 
CCI
GALDERMA LABORATORIES, L.P.  Page 21 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
Table 2 - Flow chart 2 - procedures for WAS assessment and administration of local anesthetic and 
Sculptra® A esthetic  
 
 
 Study Phase:  Screening/ 
Initial Tx  Additional Treatment (If 
needed)  
(3 Week Intervals)  
Time point:
 
Procedures  Visit 1 
Screening/ 
Initial 
Visit 2  Visit 3  
If needed   
Visit 4  
If needed  
 
Day 1  Week 3
± 3 days Week 6  
± 3 days Week 9  
± 3 days 
Assess WAS prior to any injection     
Measure the length of NLF and other facial 
wrinkles requiring treatment     
Standardized photography prior to any injection     
Administer local anesthetic (if applicable)     
Measure area of treatment grid     
Assess WAS prior to injection of Sculptra® 
Aesthetic     
Administer Sculptra® Aesthetic     
Assess WAS after injection of Sculptra® 
Aesthetic     
Standardized photography before/after 
injection of Sculptra® Aesthetic (ie “post- 
treatment photographs”)     
  Tx=treatment; WAS = wrinkle assessment score 
 
Procedures should be followed  in the order given above.  Administration of Sculptra® 
Aesthetic at Visits 2, 3, and 4 is based on need as  determined by the Investigator.  If it is 
determined that treatment with Sculptra® Aesthetic is not needed, then only the first 3 
procedures must be performed. 
  
GALDERMA LABORATORIES, L.P.  Page 22 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 3 LIST OF ABBREVIATIONS 
 
 
 
ALT alanine aminotransferase  
AST aspartate aminotransferase  
CaHA calcium hydroxylapatite 
Completer2 subjects who receive at least one Sculptra® Aesthetic injection and finish the second year visit 
Completer5 subjects who receive at least one Sculptra® Aesthetic injection and finish the fifth year visit  
CRF case report form 
CSO clinical supply operation  
DRF discrepancy resolution form  
EU European Union 
FDA Food and Drug Administration 
HIPAA Health Insurance Portability and Accountability Act 
HIV human immunodeficiency virus 
ICH International Committee on Harmonization 
IP investigational product 
IRB Institutional/Ethics Review Board 
ITT intent-to-treat 
IVRS interactive voice response system  
IWRS interactive web response system  
LED light emitting diode 
NLF nasolabial fold  
PAS postapproval study  
PLA polylactic acid  
PLLA poly-L-lactic acid 
PMA premarket approval application 
PMMA polymethyl methacrylate 
Pnp2 the percentage of subjects who experienced any injection site nodule and/or papule adverse event 
at 2 years  
Pnp5 the percentage of subjects who experienced any injection site nodule and/or papule adverse event 
at 5 years  
Poci2 the percentage of subjects who experienced any adverse event of interest other than nodule or 
papule at 2 years 
Poci5 the percentage of subjects who experienced any adverse event of interest other than nodule or 
papule at 5 years 
PP per protocol 
PTC product technical complaint 
SWFI sterile water for injection 
TEAE treatment-emergent adverse event 
ULN upper limit of normal 
USP United States Pharmacopeia 
WAS wrinkle assessment score 
 
   
GALDERMA LABORATORIES, L.P.  Page 23 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 4 INTRODUCTION AND RATIONALE 
 
Aging facial skin is a challenge for dermatolog ists and plastic surgeons .  The loss of elastic 
elements resulting from decreased collagen synt hesis creates age lines, which can be quite 
worrisome for those affected.1,2   Aging also induces volumetric changes in the face that 
result from alterations of the soft tissues induc ing their redistribution.  The repositioning of 
the soft tissues with age is best characterized as a forward drift from the malar region into the 
nasolabial zone and jowl.3,4 
 
Topical treatment is usually in effective for deep wrinkles.1,2   In these cases, surgical correction 
by means of implantation is possible. 
 
Injectable devices have become an increasingly popular alternative to surgical interventions for facial cosmetic enhancement.
5   Simultaneously, the number of  these products available 
to practitioners has increased in  recent years, offering vari ous durations of  correction and 
subject outcomes. 
 
Short-term passive fillers, such as collagen a nd hyaluronic acid, correct lines and wrinkles via 
the addition of exogenous material to the dermis.6 In general, the duration of passive fillers 
primarily depends upon thei r viscosity and chemical composi tion, and efficacy ranges from 3–
12 months.7 
 
Agents such as polyacrylamide gel a nd polymethyl methacrylate (PMMA), add 
permanent volume to the face for the correction of specific defects.8 
 
Injected calcium hydroxylapatite (CaHA) has been  noted to have a dura tion of approximately 9 
to 12 months, and has been used for the corre ction of human immunodeficiency virus (HIV)-
related facial lipoatrophy, as well as the correction of moderate-to-severe wrinkles.8,9,10 
 
Injectable poly-L-lactic acid (PLLA), the investigational product (IP) in this study, has the legacy Dermik Laboratories compound code DL6049.  Injectable PLLA is  marketed as New 
Fill
® in Europe and as Sculptra® Ae sthetic in the United States.  It is considered to be a 
device.  It has been used successfully in th e European Union (EU), Brazil, Australia and in 
North America to correct the signs of facial lipoatrophy associated with HIV.11-14 Injectable 
PLLA is also approved in the EU, Brazil, Austra lia and Canada for cosme tic use. In the United 
States, injectable PLLA is indicated for use in  immune-competent  people as a single regimen 
for correction of shallow to deep nasolabial fold  contour deficiencies an d other facial wrinkles 
in which deep dermal grid pa ttern (cross-hatch) injection te chnique is appropriate. (This 
corresponds to wrinkle assessment scores (WAS) of 2 to 4 [see Appendix II ] and the cross-
hatch injection techni que presented in Figures 3 to 7 in th e Instructions for Use section of the 
Sculptra® Aesthetic package in sert). Henceforth, in this document, DL6049 or injectable 
PLLA will be referred to as Sculptra® Aestheti c, unless there is a specific need to use the 
compound code or injectable PLLA.  The prot ocol number for this post approval study is 
GLI.04.SPR.US10321.   
GALDERMA LABORATORIES, L.P.  Page 24 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 The safety and effectiveness of Sculptra® Aesthetic for the treatme nt of nasolabial fold (NLF) 
wrinkles was evaluated in a randomized, evaluator blinded, pa rallel group, multicenter clinical  
trial in the US (Study DL6049- 0301). Immuno-competent subjects with previously untreated 
NLF wrinkles with WAS of 2 (shallow) to 4 (deep) pa rticipated in the study. 
 
The study consisted of 2 phase s, namely the controlled phase  (0 to 13 months Sculptra® 
Aesthetic versus Cosmoplast ) and the long-term surveill ance phase (13 to 25 months; 
Sculptra® Aesthetic only). 
 
During the controlled phase of the study, subjects received bilateral injections of either 
Sculptra® Aesthetic or Cosmopl ast in both NLF wrinkles fo r a maximum of 4 injection 
sessions over 9 weeks. Study treatment was plan ned to be stopped when both NLF wrinkles 
reached optimal correction of WAS equal to 1 or 0, or until the maximum of 4 injection 
sessions were completed. 
 
Subjects treated with Sculpt ra® Aesthetic and Cosmoplast during the controlled phase 
showed a consistent, progressive , and significant improvement over baseline for the primary 
variable WAS beginning 3 weeks after the last treatment.  Though the treatment effect of 
Sculptra® Aesthetic was mainta ined for up to 13 months, the Cosmoplast treatment effect 
returned to baseline within 3 m onths of the final treatment. 
 
Commonly occurring short-term injection-rela ted site reactions were reported in both 
treatment groups. In this clinical study the percentage of subjec ts with nodules and/or papules 
was greater after Sculptra® Ae sthetic (17.2% [20 of 116]) than after the control treatment 
(12.8% [15 of 117]). This reflects 8 Sculptra ® Aesthetic subjects w ho experienced nodules, 
10 Sculptra® Aesthetic subjects who experienced papules, and 2 Sculptra ® Aesthetic subjects 
who experienced both nodules and papules. Afte r the first Sculptra® Aesthetic injection 
session, time to onset for nodules was 160 days  (median) and 209 days (mean), and for 
papules, time to onset was 55 da ys (median) and 159 days (mean ). After Sculptra® Aesthetic 
injection, the duration of nodul es was 100 days (median) and 180 (mean) days, and for 
papules, was 110 days (median) and 176 days (m ean). One subject with a papule required a 
single intralesional corticosteroid injection and the event resolved. For 3 subjects with 
nodules/papules, no information on outcome was available at the end of the 25-month 
extension phase study. For all remaining subj ects, nodules/papules resolved spontaneously. 
None of these events were reported as a seriou s adverse event by the investigator.  Table 3  
shows adverse event data that were collected fr om patient diaries over the controlle d phase (0 
to 13 months Sculptra® Aest hetic versus Cosmoplast). 
 
 
GALDERMA LABORATORIES, L.P.  Page 25 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 Table 3 - Intensity of adverse events after the initial treatment session, recorded in the 14 day subject diary (Controlled Pha se) – All-
Treated Population  
 
 
 
 
  
 
 
 
Injection Procedure  
Related Event   
SCULPTRA Aesthetic  
(First Treatment Session: N = 116)Cosmoplast  
(First Treatment Session: N = 117)
 
  
 
Total 
subjects 
reporting symptomsa 
n (%) Severity of Adverse Eventa  
 
 
Total subjects 
reporting symptomsa 
n (%) Severity of Adverse Eventa 
 
Mild 
n  
Moderate 
n  
Severe 
n  
Missing 
n  
Mild 
n  
Moderate 
n  
Severe 
n  
Missing 
n 
 
Localized Swelling 
Localized Tenderness 
Localized Redness 
Post-Injection Site Pain 
Localized Bruising 
Bleeding from Site(s) Localized Itching 
Nodules / papules / 
lu
mps  
94 (81.0)  
 
94 (81.0)  
 
90 (77.6)  
 
82 (70.7)  
 
75 (64.7)  
 
39 (33.6)  
 
23 (19.8)  
 
 
4 (3.4)  64 
 
63 
 
63 
 
58 
 
44 
 
29 
 
14 
 
 
2 24 
 
24 
 
23 
 
16 
 
22 
 
3 
 
1 
 
 
1 5 
 
2 
 
1 
 
1 
 
6 
 
0 
 
0 
 
 
0 1 
 
5 
 
3 
 
7 
 
3 
 
7 
 
8 
 
 
1 76 (65.0) 
 
83 (70.9) 
 
88 (75.2) 
 
65 (55.6) 
 
50 (42.7) 
 
43 (36.8) 
 
34 (29.1) 
 
 
14 (12.0) 60 
 
62 
 
63 
 
50 
 
26 
 
33 
 
24 
 
 
4 13 
 
16 
 
23 
 
7 
 
18 
 
5 
 
6 
 
 
7 1 
 
1 
 
1 
 
1 
 
1 
 
0 
 
1 
 
 
1 2 
 
4 
 
1 
 
7 
 
5 
 
5 
 
3 
 
 
2 
 
Otherb  
19 (16.4) 7 8 1 3 22 (18.8) 11 6 3 2 
 
Total  
113 (97.4) 48 54 11 0 110 (94.0) 61 42 5 2 
 a   Subjects experiencing multiple episodes of a given adverse event are counted once for that event within the most severe categor y. 
 b    Subjects who reported multiple events in the “Other” category are counted only once within the most severe category. Adverse Ev ents reported as “Others” 
are headache, dry skin, skin peeling, rash at injection, pimples, improvement of allergy symptoms, needle marks, sinus pressure , bruising, mouth sores, 
tenderness and twitching of nostril.  
CCI
GALDERMA LABORATORIES, L.P.  Page 26 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 After the first Sculptra® Aesthe tic injection sessio n, time to onset for nodules was 160 days 
(median) and 209 days (mean), and for papules, time to onset was 55 days (median) and 159 
days (mean). After Sculptra® Aesthetic injection, the dura tion of nodules was 100 days 
(median) and 180 days (mean), and for papule s, was 110 days (median) and 176 days (mean) 
(Table 4). One subject with a papule required a single corticosteroid injection and the event 
resolved. For 3 subjects with nodules/papules, no  information on outcome was available at the 
end of the 25-month extension phase study. For all remaining subjects, nodules/papules 
resolved spontaneously. None of these events we re reported as a serious adverse event by the 
investigator. Table 4 shows injection-related side  effects that were collected from the patient 
diaries and from the phys icians over the entire course of the study. 
 
 
Table 4 - Number of subjects with injection-related side effects observed in Sculptra Aesthetic US 
clinical study  
 
SIDE EFFECTS TYPE  
Immediate, as recorded in subject diaries 116Subjects 
N (%) 
Localized Swelling 
Localized Tenderness 
Localized Redness Post-Injection Site Pain 
Localized Bruising  Bleeding from Site(s) Localized Itching 
Other 
DELAYED, as reported by physicians  
Nodules and papules 
Delayed injection site pain* Average time to appearance after first injection:  
 
Nodules  
 Papules 
 
Average time of duration: Nodules  
 Papules  94 (81.0%)  
94 (81.0%)  
90 (77.6%)  
82 (70.7%)  
75 (64.7%)  
39 (33.6%)  
23 (19.8%)  
19 (16.4%)  
 
20 (17.2%)  
1 (0.9%)  
 
209 days 
159 days 
 
180 days 
176 days 
*one subject reported mild injection site pain approximately 20 months after 
first injection, no information on outcome was available at the end of the 25 
month extension phase study 
 
Most side effects were mild and resolved on their own.  Fi ve new Sculptra® Aesthetic -
related events were reported more than 13 months after fi rst injection with Sculptra® 
Aesthetic in 3 subjects: 2 papul es (1.9%), 1 nodule (0.9%) and 2 injection site pain (0.9%). 
 
Study subjects who had received Sculptra® Aest hetic in the controlled phase of the study 
were additionally followed for safe ty and efficacy at Months 19 and 25 after the last injection 
session. 
 
During the long-term surveilla nce phase, the Sculptra® Ae sthetic group continued to 
demonstrate statistically significant improvement s over baseline in WAS.  The effect depended 
on baseline WAS (see Figure 1).  
  
GALDERMA LABORATORIES, L.P.  Page 27 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 Figure 1 – Wrinkle assessment scores throughout Study DL6049-0301  
 
 
 
 Source:  Sculptra® Aesthetic package insert 
 
The experience with Sculptra® Ae sthetic in immune-com petent subjects with darker skin types  
(ie, Fitzpatrick types18 IV-VI [see Appendix I ]), was limited in the above  study (ie, 22 out of 
116 subjects treated with Sculpt ra® Aesthetic had skin type IV-VI). Thus, the Sponsor has 
committed to perform this postapproval study (PAS) to assess the safety of Sculptra® 
Aesthetic on at least 100 evalua ble subjects with Fitzpatrick sk in type IV-VI (including at 
least 15 with Fitzpatrick skin ty pe IV and 85 with Fitz patrick skin type types V or VI) up to 5 
years (ie, completion of the follow-up phase).  This PAS, in conj unction with the above 
pivotal study, would pr ovide significant information to confirm the safety of Sculptra® 
Aesthetic in darker skin types over a longer period of observat ion and to asse ss device-related 
long-term incidence of  chronic inflammation. 
 
For detailed information regarding the efficacy and sa fety of Sculptra® Aesthe tic, please refer to 
the Sculptra® Aesthe tic package insert.   

GALDERMA LABORATORIES, L.P.  Page 28 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 5 STUDY OBJECTIVES 
 
5.1 PRIMARY 
 
The primary objective of the study is to assess the long-term safety of  Sculptra® Aesthetic 
in immune-competent subjects  as a single regimen for co rrection of WAS 2 to 4 NLF 
contour deficiencies and other facial wrinkles in which deep  dermal grid pattern (cross-
hatch) injection techniqu e is appropriate, for th e following variables: 
 The device-related long-term incidence of chronic inflammation (nodules, papules, 
granulomas, skin necrosis, hypersensitivity, and other injection site reactions) in subjects 
with Fitzpatrick skin type I-VI. 
 The incidence of hypertrophic scarring, keloid formation, and changes in skin 
pigmentation in subjects with Fitzpatrick skin type IV-VI. 
 
 
5.2 SECONDARY 
 
Secondary objectives in clude the following: 
 To evaluate the time to onset, duration, severi ty, relationship to Sculptra® Aesthetic and/or 
injection procedure, and outcome of all adverse events, includ ing adverse events mentioned 
under the primary objectives, during the course of the study, by Fitzpatrick skin type. 
 To evaluate the change in the WAS from baseline to post-tr eatment follow-up time points 
at Months 6, 13, and Years 2, 3, 4, and 5 in NLFs and other facial wrinkles. 
 To evaluate Investigator/subject global a ssessments at Months 6, 13, and Years 2, 3, 4, 
and 5. 
 
6 STUDY DESIGN  
 
6.1 DESCRIPTION OF THE PROTOCOL 
 
This is prospective, open-label; multicenter US study to evaluate the long-term safety of  
Sculptra® Aesthetic in immuno- competent subjects, stratified by Fitzpatrick skin types18 I-III, 
IV, and V-VI (see Appendix I ). 
 
For a detailed description, the study procedures are summarized  in the study flowchart in 
Section 2.  
 
This clinical study will be c onducted in the US with  approximately 863 subjects at a minimum 
of 20 sites, with a planned mini mum of 15 subjects per site.  
 
 
GALDERMA LABORATORIES, L.P.  Page 29 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
6.2 DURATION OF STUDY 
 
The study participation for each subject will be  approximately 5 years in duration. Subjects 
will receive open-label treatment at the screening/initial treatment visit (Visit 1, Day 1 – 1st 
injection session). Subjects will  continue to receive open-lab el treatment for up to 9 weeks 
(Visit 2, Week 3 [2nd injection session]; Visit 3, Week 6 [3rd injection session]; and Visit 4, 
Week 9 [4th injection session]) if needed and determin ed by the clinical study Investigator. 
Subjects will continue with fo llow-up visits at Months 3, 6, 9,  and 13, and Years 2, 3, 4, and 5. 
 
6.3 INTERIM ANALYSIS 
 
Interim analyses are planned following comple tion of all subjects’ Month 13, Year 2, 3, and 
4 follow-up visits. All safety and efficacy data up  to the interim cut-off date will be cleaned, 
interim locked, analyzed and reported.  
 
 
 
7 SELECTION OF SUBJECTS 
 
7.1 NUMBER OF SUBJECTS PLANNED 
 
It is planned to enroll a total of 863 subjects (inc luding at least 22 with Fi tzpatrick skin type IV 
and 122 with Fitzpatrick skin type V-VI) in order to have at leas t 604 evaluable subjects (at least 
15 with Fitzpatrick skin type IV and 85 with Fitz patrick skin type V-VI) at the end of the study 
(please refer to Section 13.2 for determination of sample size). 
 
7.2 INCLUSION CRITERIA 
 
In order to be eligible to enter into the study, subjects must fulfill all of the following 
inclusion criteria: 
 
1.   Subjects seeking correction of shallow to deep NLF contour deficien cies. Subjects must 
have a score of ≥ 2 and ≤ 4 on the photo-numeric wrinkl e assessment scale of both the 
right and left NLFs at entry as assess ed by the clinical investigator (see Appendix II ). 
 
Subjects may also have other fa cial wrinkles (ie, cheek line s, marionette lines, and chin 
crease/chin fold) using the Assessment S cale for Other Facial Wrinkles (see Appendix III ) 
for which deep dermal grid pattern (cross -hatch) injection tec hnique is appropriate. 
 
2.   Subjects must sign  a statement of informed consent including full copy right release of 
photographs to the Sponsor; init ial and date “A Patie nt’s Guide to Treatment with Sculptra® 
Aesthetic”; and Health Insura nce Portability and Accountabil ity Act (HIPAA) authorization.  
CCI
GALDERMA LABORATORIES, L.P.  Page 30 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
Note: No waiver, prospective or retrospe ctive, to deviate in  any way from the 
inclusion/exclusion criteria for clinical study subjects, defined in the study protocol, can 
be granted to clin ical investigators.  
 
7.3 EXCLUSION CRITERIA 
 
Subject will not be  enrolled in the study if any of the following exclusion criteria are 
present/met: 
 
1.   Subjects seeking, at entr y into the study, correction of  other facial wrinkles with 
Sculptra® Aesthetic in the following anatomical sites/lines: horizontal forehead lines, 
glabellar frown lines, periorbital lines, periau ricular lines, upper lip lines, lower lip 
lines, corner of the mouth lines and/or horizontal neck folds. 
 
2.   Subjects who are less than 18 or greater than 75 years of age. 
 
3.   Subjects with a score of  0, 1, or 5 on the photo-numeric wrinkle assessment scale of 
either the right or left NLFs (see Appendix II ). 
 
4.   Personal history of allergic/anaphylactic reactions in cluding hypersensitivity to 
local anesthetics (eg, lidocaine, etc.), la tex, or any of the Sculptra® Aesthetic 
constituents. 
 
5.   History of facial skin cancer or recurre nce of facial skin cancer other than basal 
cell carcinoma within 5 years. 
 
6.   Known history of keloids or  bleeding/coagulation disorder. 
 
7.   History of human immunodeficiency vi rus, diabetes, connec tive tissue disorders 
(eg, lupus, scleroderma), or other serious systemic di sease (eg, sarcoidosis). 
 
8.   Presence of surgical or non-surgi cal scars in the area  to be treated. 
 
9.   Active inflammatory process or infection in  the area to be treate d (skin eruptions such 
as cysts, pimples, rashes, herpes simple x, herpes zoster, cancerous/pre-cancerous 
lesions), or any other active or  serious skin disease (eg, ecz ema, psoriasis of the face, 
severe rosacea, se vere acne, etc.). 
 
10. Subjects with an American Society of Anesth esiologists’ Physical Status Classification  
System Score15 of ≥ P3 (P3 = a subject with seve re systemic disease) (see Appendix IV ). 
 
11. Subjects with medical conditions that mi ght require the use of  immunosuppressive 
(except for oral steroids that  can be used for less than 1 month over the duration of the 
study) or anti-inflammatory medications duri ng the trial (eg, severe  asthma, rheumatoid 
arthritis, etc.).  
GALDERMA LABORATORIES, L.P.  Page 31 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 12. Viral, chemical, or any active hepatitis within the past year. 
 
13. Planned surgical procedures wi th incisions and suturing in th e area to be treated during 
the course of the study. 
 
14. Planned major facial aesthe tic procedure/plastic surgery (eg, rhinoplasty [with or 
without implant], facelift, congenital defect re pair, etc.) during the course of the study. 
 
15. Subjects who have or  plan to use exclusionary trea tments/medications/devices, as 
described below (or who are unable to comply with concomitant therapy 
restrictions as described in Section 8.8 ): 
 
a.   Cosmetic permanent filler-type inj ectable products (eg, PMMA, etc) in the 
facial treatment area at any time prior to or during the study. 
 
b.   Immunosuppressive medications including systemic steroids (eg, oral prednisone) 
within 6 months of treatment or for mo re than 1 month of  treatment over the 
duration of the study. Intranasal/inhale d or topical steroi ds are acceptable. 
 
c.   Previous injectable PLLA treatment in the face. 
 
d.  Temporary dermal fillers within 18 m onths of treatment in the same area to 
be treated with Sculptra® Aesthetic. 
 
e.  Botulinum toxin (any type) within 6 m onths of treatment in  the same area to 
be treated with Sculptra® Aesthetic. 
 
f. Subjects receiving antiplatelet (eg, full st rength aspirin [> 81 mg/per day], high dose 
aspirin-containing products , clopidogrel, etc.); anticoagulant (eg, coumarin 
derivatives, unfractionated heparin, low molecular weight  heparin, selective factor 
Xa inhibitor, thrombin inhi bitor, etc.) or nonsteroidal anti-inflammatory agents; in 
whom, in the Investigator’s opinion, ad ministration of Scul ptra® Aesthetic may 
cause procedure- related complications at the injection site. 
 
g.   Prescription facial wrinkle therapie s that include retinoic acid derivatives, 
prescription strength alpha-hydroxyacids and beta-hydroxyacid s and idebenone 1% 
in the area to be treated less th an 3 months prior to enrollment. 
 
h.   Hand-held light therapy devices fo r personal use such as LED or laser 
resurfacing, intense light pulse therapy or radiofrequency in the area to be 
treated less than 6 months prior to enrollment. 
 
16. Women who are pregnant, nursi ng or intend to become preg nant over the duration of 
the study or women who are of childbear ing potential not protected by effective 
contraceptive method of birth co ntrol  and/or who are unwillin g or unable to be tested 
for pregnancy. Pregnancy status must be  checked by urine testing at Visit 1. 
 
Effective birth control is de fined as follows: (1) have had a hysterectomy or tubal 
ligation; or (2) use oral/systemic contraceptives  for at least 3 months  prior to the start 
of the study; or (3) use an intrauterine device; or (4) use double- barrier (eg, condom 
and spermicidal foam, gel or inse rt or condom and diaphragm); or (5) use implants or 
GALDERMA LABORATORIES, L.P.  Page 32 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 injectables, for at least 28 days prior to the start of the study; or (6) be 
postmenopausal for at least 1 year prior to entry into the study.   The birth control 
regimen must be maintained throughout the study. 
 
17. Subjects who are unwilling or unable to give written cons ent to participate in the 
investigation or unable to comply with the requirements of the clinical trial 
protocol. 
 
18. Subjects who have received an y experimental drug or devi ce within the previous 3 
months prior to first treatment. 
 
19. Subjects who are known alc ohol or drug abusers. 
 
20. Subjects who are suffering from any psyc hological condition, or are under treatment 
for any condition which, in the opinion of  the Investigator and/or consulting 
physicians(s) may constitute an unwarranted risk or which may affect the subjects’ 
compliance or adherence to study procedures. 
 
Note: No waiver, prospective or retrospe ctive, to deviate in any way from the 
inclusion/exclusion criteria for clinical study  subjects, defined in the study protocol, 
can be granted to clin ical investigators. 
 
8 TREATMENTS 
 
8.1 INVESTIGATIONAL PRODUCT 
 
The Sponsor will supply the Sculpt ra® Aesthetic and the sterile wa ter for injection (SWFI).   
Only Sculptra® Aesthetic and SWFI provided by the Sponsor can be used for this study.  
 
 The investigational site  will supply the syringes and other materials needed for the 
injections, such as alcohol wipes and other types of topical/local anesthetics (if used). See package insert for a complete list of required supplies. The investigational site will also be 
responsible for proper disposal of syring es and any other bioh azard material(s). 
 
Background therapy (eg, treatments for underly ing disease) or other drug therapy not 
identified in this study protocol wi ll not be supplied by the Sponsor. 
 
Sculptra® Aesthetic is an injectable impl ant that contains PLLA, a biocompatible, 
biodegradable, synthetic polymer from the alpha -hydroxy-acid family.  
 
 
 
CCI
CCI
GALDERMA LABORATORIES, L.P.  Page 33 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 Sculptra® Aesthetic is recons tituted with 5 mL sterile water for injection (SWFI) as 
outlined in the package insert. 
 
Each subject will receive a single regimen of Sc ulptra® Aesthetic to correct shallow to deep 
(WAS 2 to 4) NLF contour defici encies and, if present, other fa cial wrinkles for which grid 
pattern (cross-hatch) injection te chnique is appropriate (ie, ma rionette lines, cheek folds, and 
chin crease/chin fold with WAS between  2 and 4 on the applicable scale [see Appendix III ]). 
A single regimen consists of up to 4 in jection sessions with 3-week  intervals, of multiple 0.1 
to 0.2 mL deep dermal injections in a grid patter n, spaced at a distance of approximately 1 cm. 
A maximum of 10 mL (5 mL per side of the face) , 2 vials of Sculptra® Aesthetic, is allowed 
at each injection sessi on and is up to the disc retion of the Investigat or. A maximum of 2.5 mL 
may be placed in each NLF at each injection se ssion. (For injection t echnique and procedures, 
see the Sculptra® Aesthetic Package insert). On ly NLFs and other facial wrinkles treated 
during Visit 1 may be treate d at subsequent visits. 
 
Study treatment injections s hould be stopped when both NLFs and other facial wrinkles 
have reached a grade of 0 to 1 on the a ppropriate wrinkle as sessment scale (see Appendix 
II and Appendix III ). Correction should be limited to no more than 100% of the defect. (If 
only 1 wrinkle has reached the targ et grade of 0 to 1 the other side should continue to be 
treated until the target grade is achieved [o r a maximum of 4 inj ection sessions and a 
maximum of 2.5 mL per NLF per session]). 
 
The selection of topical and/or injectable anesthetic agents fo r local anesthesia will be at 
the discretion of the Investig ator; however, injectable anes thetics should not be mixed 
into the Sculptra® Aesthetic vials. 
 
8.2 COMPENSATION FOR LACK OF BLINDING 
 
This is a single group (open la bel) study; however every effo rt will be implemented to 
prevent bias. 
 
 
8.3 METHOD OF ASSIGNING SUBJECTS TO TREATMENT GROUP 
 
After a subject has signed the informed c onsent form, a unique subject number will be 
assigned. This subject number that will be entered in a case report form (CRF) used to 
identify that subject over the co urse of the clinical trial. 
 
Subjects will be stratified according to their Fitzpatrick skin types18 (see Appendix I ) .When a 
subject is withdrawn from the study, the subjec t will not be permitted to re-enter or rescreen 
into this clinical trial. 
 
 
 
 
GALDERMA LABORATORIES, L.P.  Page 34 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 8.4 PACKAGING AND LABELING 
 
The Sculptra® Aesthetic w ill be packaged and labeled by the Sponsor or designee, for clinical 
study use only. The Sculptra® Aesthetic will have a tear-off portion on the label. Each tear-off 
label will be removed and will be affixed to the source documents.   Labeling will include a 
unique identifier number to permit accountability of Sculptra® Aesthetic, to individual vials.     
 
The SWFI and  will be s upplied in bulk, with commercial labeling. 
 
8.5 STORAGE CONDITIONS 
 
Sculptra® Aesthetic is to be stored at room temperature, defined as 15°C to 30°C (86°F). 
DO NOT FREEZE. Refrigeration is not required. The Sculptra® Aesthe tic must be in a 
secured, limited access area. After reconstituti on, Sculptra® Aesthetic can be used and 
stored at room temper ature for up to 72 hours. 
 
SWFI and  will be stored according to the manufacturer’s recommendations. 
 
A daily temperature log must be maintained  to ensure proper storage for study-supplied 
Sculptra® Aesthetic, SWFI  and . 
 
 
8.6 RESPONSIBILITIES 
 
The Investigator, the pharmacist, or other personnel a llowed to store and di spense the Sculptra® 
Aesthetic will be responsible for ensuring that th e Sculptra® Aesthetic used in the clinical trial 
is securely maintained as specified by the Sponsor and in accordance with the applicable 
regulatory requirements. 
 
All Sculptra® Aesthetic shall be di spensed in accordance with the clinical trial protocol. It is 
the Investigator’s responsibility to ensure that an accurate record of all Sculptra® Aesthetic 
(dispensed and returned) is maintained. 
 
Any quality issue noticed with the receipt or use of the Sculptra® Aesthetic  (deficient product in 
condition, appearance, pertaining documentation, labeling, expiration da te, etc.) should be 
promptly reported to the S ponsor or designee as a product technical complaint (PTC). 
Under no circumstances will the Investigator supply  Sculptra® Aesthetic to a third party, allow 
the Sculptra® Aesthetic, SWFI or  to be used othe r than as directed by this 
clinical trial protocol, or  dispose of Sculptra® Aest hetic in any other manner. 
 
The following information for Sc ulptra® Aesthetic and local an esthetics (if used) will be 
recorded in the subject’s medi cation record at each visit: 
 Generic and trade name of local anesthetics 
CCI
CCI
CCI
CCI
GALDERMA LABORATORIES, L.P.  Page 35 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  Concentration, frequency and volume of anesthetics injected/applied 
 Date and time of anesthetic administration 
 Location of Sculptra® Ae sthetic administration 
 Date and time of Sculptra ® Aesthetic administration 
 Amount of Sculptra® Aesthetic  used per injection area/W AS/session (derived from 
volume injected, length and width of injection area) 
 Number of Sculptra® Aesthetic  injection sessions and time interval between injection 
sessions derived from date  and time of Sculptra® Aesthetic administration 
 
 
8.7 RETRIEVAL AND/OR DESTRUCTION OF INVESTIGATIONAL PRODUCT 
 
 
8.7.1   Partially used or unused treatment 
 
It is the Sponsor’s responsibility to ensure the destruction of all pa rtially used or unused 
Sculptra® Aesthetic. A detailed treatment log of the unused, retu rned Sculptra® Aesthetic will 
be established with the Investig ator (or the pharmacist) and countersigned by the Investigator 
and the monitoring team. The site will be responsible for the dest ruction of the used Sculptra® 
Aesthetic vials,  and the SWFI. All unused Sculptra® Aesthetic vials, 
 and SWFI will be returned to the Sponsor. 
 
All used/unused Sculptra® Aesthetic,  and SWFI will be stored at the 
study site until it is reconciled by the Sponsor /designee. The Sponsor/designee will verify 
that a final report of accountabil ity (including product disposition) is prepared to the vial 
unit level and maintained in the Investigator study file. 
 
 
8.7.2   Potential recall 
 
A potential defect in the quality  of Sculptra® Aesthetic may be  subject to initiation by the 
Sponsor of a recall procedure. In  this case, the Investigator wi ll be responsible for promptly 
addressing any request made by the Sponsor, in order to recall Sculptra® Aesthetic and 
eliminate potential hazards. 
 
 
8.8 CONCOMITANT TREATMENT 
 
No concomitant facial injectable dermal fillers (including Sculptra® Aesthetic) will be 
allowed during the first 2 years after the initial single treatment regimen. 
 
The following medications/fillers an d procedures are prohibited in the facial area for the first  
2 years of the study, after which they may be used only above th e zygoma at the discretion of the 
Investigator:  
 Procedures/treatments 
CCI
CCI
CCI
GALDERMA LABORATORIES, L.P.  Page 36 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 - Botulinum toxin products (eg, Botox cosmetic®  injections, etc.) 
 
- Nonpermanent cosmetic filler-type products (eg, bovine collagen, 
hyaluronic acids, etc.). 
 
- Cosmetic permanent filler-type injectable products (eg, PMMA, 
silicone, preformed implant, etc.). 
 
- Superficial dermal resu rfacing procedures including chemical peel, 
dermabrasion, or micr oderm treatments. 
 
- Deep dermal resurfacing proce dures including laser therapy. 
 
- Prescription facial wrinkle therapies, prescription strength alpha-hydroxyacids 
and beta-hydroxyacids applie d in the treatment area. 
 
The following treatments/medications are prohib ited for the entire 5-year  duration of the study : 
 Any investigational product or device 
 Procedures/treatments 
 
- Sculptra® Aesthetic treatmen t in any anatomical site 
 
- Cosmetic permanent and nonpermanent fille r-type injectable products in the 
Sculptra® Aesthetic treated facial area 
 
- Deep dermal resurfacing procedur es including laser therapy in the 
Sculptra® Aesthetic treated facial area 
 
- Superficial dermal resurfaci ng procedures including chemical peel, dermabrasion, 
or microderm treatments in the Sculpt ra® Aesthetic treated facial area. 
 Medications 
 
- Immunosuppressive medications includi ng systemic steroids (eg, oral 
prednisone) for more than 1 month over the duration of the study. 
Intranasal/inhaled and topical steroids are allowed. 
 Devices: 
 
- Hand-held light therapy devices for personal use such as light emitting diode 
(LED) or other in the treatment area. 
 Medications at the discre tion of the Investigator: 
 
- Subjects requiring antiplatelet (eg, full st rength aspirin [> 81 mg/per day], high-
dose aspirin-containing products, clopidogrel,  etc.); anticoagulant (eg, coumarin 
derivatives, unfractionated heparin, low mol ecular weight heparin, selective factor 
Xa inhibitor, thrombin inhi bitor, etc.) or nonsteroidal anti- inflammatory agents; 
in whom, in the Investigator’s opinion, administration of Scul ptra® Aesthetic may 
cause procedure-related complications at the injection site. 
 
Note: Other products for treatment of concurrent conditions are allowed providing, 
as judged by the Investigator, they w ill not interfere with the evaluation of 
Sculptra® Aesthetic.  
 
GALDERMA LABORATORIES, L.P.  Page 37 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 8.9 POST-STUDY TREATMENT 
 
Sculptra® Aesthetic is provided to  the subject at no cost during participation in this clinical 
trial. Sculptra® Aesthetic is commercially accessible to the subject poststudy. 
 
 
8.10 TREATMENT ACCOUNTABILITY AND COMPLIANCE 
 
The Investigator or his/her desi gnee will ensure accountability by completion of logs at the 
time of Sculptra® Aesthetic /SWFI usage. The Monitor assigned to the study will check 
Sculptra® Aesthetic and SWFI supplies received  at the site and compare them with the 
unused Sculptra® Aesthetic and SWFI supplies  and with the treatment log forms. The 
Sculptra® Aesthetic will have tear-off labels to facilitate accounting. 
 
The Sponsor/designee will verify  that a final report of ac countability (including product 
disposition) is prepared to the Sculptra® Aesthetic and SWFI vial unit level and maintained 
in the Investigator study file. 
 
 
8.11 PRODUCT TECHNICAL COMPLAINTS 
 
Product technical complaints s hould be reported to the Spons or/designee. A PTC is any 
written, electronic, or oral co mmunication that alleges deficiencies related to the identity, 
quality, reliability, safety, durability, effectiv eness, or performance of a drug, device or 
combination product. Examples ma y include but are not limited to: appearance issues, odor, 
broken vials, damaged stoppers, low fills, and foreign matte r in the product, lack of 
effectiveness.  These complaints may or may not  represent a potential risk to the subject. For 
these types of events, a PTC Form must be comp leted by the site personnel and forwarded to 
the study monitor on the next working day. 
 
As Sculptra® Aesthetic is  considered a medical device, any a dverse events related to the device 
and all serious adverse events are also consider ed PTCs. These PTCs will be reported to  the 
Sponsor through the CRF at the same tim e as they are entered by the site. 
 
9 ASSESSMENT OF THE INVESTIGATIONAL PRODUCT 
 
9.1 SAFETY 
 
9.1.1 Primary safety criteria 
 
All adverse events will be collected thro ughout the study including, but not limited to, 
injection- site adverse events such as: 
 Hypertrophic scarring, 
 Keloid formation, 
 Changes in skin pigmentation at the site of injection compared to adjacent skin, 
GALDERMA LABORATORIES, L.P.  Page 38 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  Papule (<0.5 cm), 
 Nodule (≥0.5 cm), 
 Granuloma (confirmed by a biopsy), 
 Skin necrosis, 
 Hypersensitivity reactions, and 
 Unexpected changes in wrinkle contour (eg,  overcorrected contours, uneven contours; 
changes in skin texture, elasticity, sensation;  and changes to local facial muscle function 
adjacent to the NLF injection site such as  smile, frown, lip pursi ng and mouth opening). 
 
The injection site adverse events  listed above are defined as a dverse events of interest in 
this study. 
 
Information collected in the CRFs will include adve rse event, location (for all adverse events), 
severity, date of onset, date of resolution, relationship to  the Sculptra® Aesthetic and 
relationship to the injection procedure, as well as medical  interventions required to 
resolve/treat the event. 
 
9.1.2 Secondary safety criteria 
 
The adverse event data (see Section 9.1.1 ) will also be used to evaluate the secondary 
safety endpoints. 
  
9.2 EFFICACY 
 
 
9.2.1 Wrinkle assessments 
 
 
9.2.1.1 Nasolabial fold assessments and measurements 
 
The NLF WAS, which is obtaine d from the wrinkle assessment scale, will be used by the 
Investigator: 
 
1.   As an initial screening tool at Visit 1 to determine inclusion criteria 
 
2.   During the treatment phase to dete rmine if further treatment is needed. 
 
3.   During follow-up visits to evaluate  any changes in the treatment area. 
 
The Investigator will classify the severity of both the left and right NLF (separately) by 
comparing the subject to the pictures on a validated16, 6-point, photo-numeric scale as 
follows (see Appendix II ): 
 
0 – no wrinkles 
1 – just perceptible wrinkle 
2 – shallow wrinkle 
GALDERMA LABORATORIES, L.P.  Page 39 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 3 – moderately deep wrinkle 
4 – deep-wrinkle, well-defined edges 
5 – very-deep wrinkle, redundant folds 
 
Each grade in the wrinkle assessment scal e is exemplified by a photograph (see Appendix II ). 
The grade represents the “best fit” based on the overall depth and length of the NLF (full point 
increments must be used). Asse ssments will be made based on a “snap-shot” at a certain time 
point and are not based on a comparison to th e pretreatment photographs .  Nasolabial fold 
WAS will be collected at the screening/initial treatment visit (Visit 1) and Visit 2, and if 
applicable, at Visits 3 and 4.  Nasolabial fold  WAS will also be obtained at Month 6, Month 
13, and Years 2, 3, 4, and 5 visits (see Section 2 , Flow chart of study procedures and Section 
12 for details). 
 
In addition, NLF measurements will be collected, at Visit 1 and Visit 2, and if applicable, at 
Visits 3 and 4.  NLF measurements will also be  collected at Month 6 Month 13, and at Years 2, 
3, 4, and 5 visits (see Section 2 , Flow chart of study procedures and Section 12 for details). 
 
9.2.1.2 Other facial wrinkle assessments and measurements 
 
The other facial wrinkles WAS will be used by the Investigator: 
 
1.   At entry to determine eligibility for treatment 
 
2.   During the treatment phase to dete rmine if further treatment is needed 
 
3.   During follow-up visits to evalua te any changes in the treatment area 
 
The Investigator will classify th e severity of both the left and ri ght facial wrinkles separately 
(ie, cheek wrinkles, marionette lines, and the severity of the chin crease/chin fold) by 
comparing the subject to the pi ctures on the Assessment Scale fo r Other Facial Wrinkles (see 
Appendix III )17 as follows: 
 
0 – no wrinkles 
1 – just perceptible wrinkle 
2 – shallow wrinkle 
3 – moderately deep wrinkle 
4 – deep-wrinkle, well-defined edges 5 – very-deep wrinkle, redundant fold 
 
Each grade in the wrinkle assessment scal e is exemplified by a photograph (see Appendix III ). 
The grade represents the “best fit” based on the ov erall depth and length of the facial fold (full 
point increments must be used). Assessments w ill be made based on a “snap-shot” at a certain 
time point and are not based on a comparison to the pre-treatm ent photographs.  Other facial 
wrinkles WAS will be collected at the screenin g/initial treatment visit (Visit 1) and Visit 2, 
and if applicable, at Visits 3 and 4.  Other facial wrinkles WAS will also be obtained at Month 
6, Month 13, and Years 2, 3, 4, and 5 visits (see Section 2 , Flow chart of study procedures and 
Section 12 for details). 
 
GALDERMA LABORATORIES, L.P.  Page 40 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
9.2.2 Investigator global evaluation 
 
Investigator global evaluations will be collect ed at the Month 6, Month 13, and Year 2, 3, 4, 
5 visits after the initial injection of study treatment (see Section 2, Flowchart of study 
procedures). Assessments will be made in compar ison to baseline (pretreatment) using the Visit 
1 center profile photograph as reference. 
 
The treating Investigator will rate the subject’s NLFs and other facial wrinkles that were 
treated for global aesthetic im provement using the following s cale (one composite score for 
both the left and right NLF and fo r any other facial wrinkle treated (eg, cheeks or marionette 
lines): 
 
+3 – Much improved 
+2 – Moderately improved +1 – Slightly improved 
0 – No change 
-1 – Slightly worse -2 – Moderately worse 
-3 – Much worse 
  
 
9.2.3 Subject global evaluation 
 
Subject global evaluations w ill be collected at the Month 6, Month 13, and Year 2, 3, 4, 5 
visits after the initial injection of study treatment (see Section 2, Flowchart of Study 
Procedures). Assessments will be made in comp arison to baseline (pre-treatment) using the 
Visit 1 center profile pho tograph as reference. 
 
The study coordinator will ask the subject to rate their NLFs  and other facial wrinkles that 
were initially treated for global aesthetic im provement compared to baseline using the 
following scale (one composite score for both th e left and right NLF a nd for any other facial 
wrinkle treated (eg, chee ks or marionette lines): 
 
+3 – Much improved 
+2 – Moderately improved 
+1 – Slightly improved 
0 – No change 
-1 – Slightly worse 
-2 – Moderately worse 
-3 – Much worse 
  
GALDERMA LABORATORIES, L.P.  Page 41 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  10 SUBJECT SAFETY 
 
10.1 ADVERSE EVENTS MONITORING 
 
Adverse events will be documented at each treatment and follow up visit, monthly safety 
contacts, and any unscheduled visits. 
 
All adverse events will be mana ged and reported in compliance with all applicable regulations 
and will be included in the final clinical study report. 
 
 
10.2 DEFINITIONS OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENT 
 
An adverse event is any untoward medical occurrence in a subject or clinical 
investigation subject admi nistered a pharmaceutical  product and which does not 
necessarily have to have a causal relationship with this treatment. 
 
In this study (additionally to other adverse events), any occurrence of a nodule, papule, 
granulomas (confirmed by a biopsy), skin n ecrosis, hypersensitivity reactions, hypertrophic 
scarring, keloid formation, changes in the sk in pigmentation compared to adjacent skin, or 
unexpected change in wrinkle contour in the Sculptra® Aesthetic injection site and 
compared to adjacent skin is to be reported as an adverse event. 
 
A Serious Adverse Device Event (SADE) an adverse event that: 
 results in death;  
 is life-threatening;  
 results in permanent impairment of a body function;  
 results in permanent damage  to a body structure; or,  
 necessitates medical or surgical interventi on to preclude permanent impairment of a 
body function or permanent damage to a body structure.  
 
10.3 SEVERITY OF ADVERSE EVENTS 
 
The severity of an adverse event is to be indicate d by the investigator according to the 
following scale: 
 
 
Mild does not interfere with routine activities, can perform 
daily functions  
 
Moderate Interferes with routin e activities, can perform daily 
functions, but with concerted efforts 
 Severe Unable to perform routine activities 
 
 
 
GALDERMA LABORATORIES, L.P.  Page 42 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
10.4 RELATEDNESS OF ADVERSE EVENT (AE) 
 
The Investigator is to classify the relations hip of an AE to the procedure or device 
according to the following definitions: 
 
Study procedure caused or contributed to the event. The Investigator is to evaluate 
the adverse event as to whether it was contributed to or caused by the injection 
procedure according to the definitions outlined in the table below. 
 
Study device caused or contributed to the event. The Investigator is to 
evaluate the AE as to whether it was c ontributed to or caused by the device 
according to the definitions ou tlined in the following table. 
 
Association  Definition  
Not related  The event c an be re adily expl ained byo t h e r
factors, does not follow a known response pattern to the device and no temporal relationship exists with the device. 
Related The AE follows a re asonable temporal
sequence related to trea tment by the device, 
follows a known or suspected response pattern and a plausible alternat ive etiology cannot be 
identified. 
 
 
10.5 OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING 
 
Adverse events  
 
All adverse events regardless of seriousness or  relationship to Sculpt ra® Aesthetic, spanning 
from the first visit planned in the clinical trial protocol/signature of the informed consent form 
(ie, occurring during the enrollment period even in the absence of any administration of 
Sculptra® Aesthetic), up to the last visit planned in the clinical trial protocol, are to be 
recorded on the corresponding page(s) included in the CRF.  The adverse event CRF must be 
completed at each visit. The sites will be pr ovided a CRF completion Guideline with detailed 
instructions on when and how to complete a ll aspects of the CRF, including the relevant 
adverse event forms for each follow-up visit. 
 
For Serious Adverse Device Events (SADEs) , in addition to completing the appropriate 
CRF pages, a SADE Reporting Form should be  completed for any reported SADEs. The 
sites will be provided a SADE  Reporting Form completion guideline with detailed 
instructions on when and how to complete  all aspects of the SADE Reporting Form. 
 
GALDERMA LABORATORIES, L.P.  Page 43 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 The SADE Reporting Form shoul d be completed and forwarde d within 24 hours of the 
investigator or any site staf f becoming aware of the SADE: 
 
Contact For SADE Reporting: 
 
This protocol
 will be supplemented with a Sa fety Management Plan (SMP) which will further 
explain the SADE reporting process. 
 
Whenever possible, symptoms should be grouped as a single  syndrome or diagnosis. The 
Investigator should specify the date of onset, da te of resolution, intens ity, action taken with 
respect to Sculptra® Aesthetic, correc tive treatment/therap y given, additional 
investigations performed, outco me and his/her opinion as to whether there is  a reasonable 
possibility that the adverse event wa s caused by the Sculptra® Aesthetic. 
 
Laboratory, vital signs, or ECG abnormalities are to be recorded as  adverse events only if they 
are deemed to be medically relevant (ie, symp tomatic, requiring corrective treatment, leading 
to discontinuation and/or fulfilling a seriousness criterion). 
 
Follow-up  
 The Investigator should take all appropriat e measures to ensure the safety of the 
subjects, notably he/she should follow up the outcome of any adverse event 
(clinical signs, laboratory values or ot her, etc) until the re turn to normal or 
consolidation of the subject’s condition; 
 In case of any SADE, the subject must be followed up until clinical recovery is complete, laboratory results ha ve returned to normal, or until progression has been 
stabilized. This may imply that follow-up w ill continue after the subject has left the 
clinical trial and that additional investigations may be requested by the monitoring team; 
 In case of any SADE brought to the attent ion of the Investigator at any time after 
cessation of Sculptra® Aesthetic and considered by him/her to be caused by the 
Sculptra® Aesthetic w ith a reasonable possibility, th is should be reported to the 
monitoring team. 
  
PPD
GALDERMA LABORATORIES, L.P.  Page 44 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
10.6 ADVERSE EVENTS AS PROD UCT TECHNICAL COMPLAINTS 
 
As Sculptra® Aesthetic is consid ered a medical device all advers e events related to the device 
and all SADEs are also considered PTCs ( Section 8.11 ). 
 
 
10.7 PREGNANCY 
 
 
 Pregnancy will be recorded as an adverse event in all cases. It will be reported 
following the same procedure as for adverse events rela ted to Sculpt ra® Aesthetic. 
 In the event of pregnancy during the study, Sculptra® Aesthetic should be 
discontinued and the Sponso r/designee should be informed by contacting the 
representative of the monitoring te am within 24 hours of knowledge. 
 In the event of pregnancy, the pre gnancy reporting form along with the SAE 
Reporting Form should be filled out and sent to the representative of the monitoring team within 24 hours of knowledge (see  Section 10.3 ). 
 Follow-up of the pregnancy (mother and fetus/child) will be mandatory through 
delivery or other end of th e pregnancy (eg, abortion) and during the 5 year follow-
up, whichever is the latest. 
 
 
11 HANDLING OF SUBJECT TEMPORARY OR DEFINITIVE 
TREATMENT DISCONTINUATION AND OF SUBJECT STUDY 
DISCONTINUATION 
 
Sculptra® Aesthetic should be continued whenever possible. In  case Sculptra® Aesthetic is 
stopped, it should be determined if the stop can be made tem porarily; permanent Sculptra® 
Aesthetic discontinuatio n should be a last resort. Any Sc ulptra® Aesthetic discontinuation 
should be fully documented in th e CRF. In any case, the subject should remain in the study as 
long as possible. 
 
 
11.1 TEMPORARY TREATMENT DI SCONTINUATION WITH 
INVESTIGATIONAL PRODUCT 
 
Sculptra® Aesthetic use at sp ecific sites in which an active inflammatory process (skin 
eruptions such as cysts, pimple s, rashes or hives) or infection is pres ent should be deferred 
until the inflammatory process has resolved and is controlled. This deferral will include the 
entire facial treatment (versus only the specific site with an active inflammatory process or 
infection). 
 
GALDERMA LABORATORIES, L.P.  Page 45 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 11.2 DEFINITIVE TREATMENT DISCONTINUATION WITH INVESTIGATIONAL 
PRODUCT 
 
 
11.2.1 Criteria for definitive treatment discontinuation with investigational product 
 
Subjects must be withdrawn from receiving any further Sculptra® Aesthetic for the 
following reasons: 
 At their own request : In case the subject wishes to discontinue treatment the 
Investigator must inquire  and document in the me dical record whether: 
 
- the subject decides to discontinue study treatment but agrees to follow-up 
procedures required by the clinical trial protocol, 
 
- the subject decides to disc ontinue study treatment a nd all follow-up procedures, 
 
- the subject decides to rev oke the consent to collect and process further data. 
 
 If, in the Investigator’s opinion , continuation in the study would be detrimental to 
the subject’s well-being (e g, serious adverse events ) 
 Pregnancy: Pregnancy will lead to definitive discontinuation of any further 
Sculptra® Aesthetic treatment in all cases. 
 
The Investigator may withdraw the subject from any further Sculptra® Aesthetic treatment 
due to the following reasons: 
 Use of prohibited concomitant medications that  will interfere with the analysis of the 
study 
 Use of another investig ational drug or device 
 
 
11.2.2 Handling of subjects after definitive treatment discontinuation 
 
Subjects will be followed up, unl ess he/she withdraws consent for follow-up,  according to 
the study procedures as specified in this protocol up to the sche duled date of study 
completion (ie, 5 years after the initial treatmen t), or up to recovery or stabilization of a 
followed-up adverse event, whichever comes last. 
 
As far as possible, after the permanent discon tinuation of Sculptra® Aesthetic treatment, all 
examinations scheduled for the final study day must be performed on a ll subjects who receive 
the Sculptra® Aesthetic but do not complete the study according to clinical trial protocol. 
 
For all definitive treatment discontinuations, when considered as confirmed, the reason for 
and date of withdrawal must be  recorded by the Investigator in the appropriat e pages of the 
CRF and in the subject’s medical records. 
 
GALDERMA LABORATORIES, L.P.  Page 46 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 11.3 PROCEDURE FOR WITHDRAWAL OF  SUBJECTS FROM STUDY FOLLOW-
UP SCHEDULE 
 
The subjects may withdraw from the study fo llow-up schedule, before study completion if 
they decide to do so, at any time and irrespective of the reason, or this may be the 
Investigator’s decision (eg, noncompliance with clinical tr ial protocol requirements): 
 All study withdrawals should be  recorded by the Investigat or in the appropriate CRF 
pages when considered as confirmed. 
 If possible, the subjects are assessed using the procedure normally planned for the end-
of- study. 
 
In the event that a subject is lost to follow- up, the Investigator should make every effort to 
contact the subject, to identify th e reason why he/she failed to a ttend the visit, and to determine 
his/her health status, including at  least his/her vital status. Atte mpts to contact such a subject 
using the information provided by the subject du ring the study, will include 3 attempts to 
contact the subject’s telephone number(s) of record, followed by 2 certified letters to the 
mailing address provided by the subject. These must be documented in the subject’s records 
(eg, times and dates of attempted telephone c ontact, receipt for certified letters that were sent). 
 
The statistical analysis plan will specify how  these subjects without primary endpoints will 
be considered. 
 
 
11.4 CONSEQUENCE 
 
Subjects who have been withdrawn from the study cannot be  reincluded in the study. Their 
subject number must not be  reused. In specific situations to be discussed between Investigator 
and Sponsor or designee, subjects who have not yet been trea ted can be reincluded in the study 
with a new number. 
 
12 STUDY PR OCEDURES 
 
12.1 VISIT SCHEDULE 
 
The purpose of the study, benefits, risks, stud y visit schedule, and th e main aspects of the 
study design will be discussed individually with each subject by  the study site personnel. The 
subject will have the opportunity to ask the Investigator any ques tions prior to enrolling in the 
study. 
 
Subjects will be recruited fr om the outpatient po pulation seeking treatment for contour 
dermal deformities of the NLF area and other facial areas.  
12.1.1 Visit 1 (Day 1) – Screening/initial treatment 
 
The following procedures will be performed during Visit 1 (listed in recommended order): 
GALDERMA LABORATORIES, L.P.  Page 47 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  The subject must sign the in formed consent form, initial and date “A Patient’s Guide 
to Treatment with Sculptra® Aesthetic,” HIPAA author ization, and photographic 
consent for the study. 
 Assign a unique subject number to the subj ect. This number will be entered in a CRF 
used to identify that subject over the course of the clinical trial. 
 Review inclusion/ex clusion criteria. 
 Review the subject’s medical history and prior/concomitant  medications and treatment 
procedures. 
 Perform physical examination (overall subject assessment and skin assessment, 
particularly the facial area; height and weight) 
 Collect vital signs (sitting heart rate and blood pressure) 
 Collect urine and perform a pregnancy test on the specime n (females of childbearing 
potential only).  Results must be ne gative to continue into the study. 
 The clinical Investigator will visually inspect the subject’s NLFs and determine 
severity based on the photo-numeric wrinkle assessment scale (see Appendix II ). 
These will be recorded as the baseline measurements. 
 
NOTE: The subject must have a grade of ≥2 and ≤4 on the photo-numeric wrinkle 
assessment scale (see Appendix II ) of the left and right NLFs to continue the 
screening process and be enrolled into the study. 
 The clinical Investigator will measure the length of the subject’s NLFs. This will 
be recorded as the ba seline measurement. 
 Assess Fitzpatrick skin type (see Appendix I ) 
 The clinical Investigator will visually in spect the subject’s other facial wrinkles 
that are planned to be tr eated and determine severity  based on the Assessment 
Scale for Other Facial Wrinkles (see Appendix III ). These will be recorded as 
the baseline measurements. 
 The clinical Investigator will measure th e length of the subject’s other facial 
wrinkles that are planned to be treate d. These will be recorded as the baseline 
measurements. 
 If the subject meets all of the study requireme nts, take photographs of each area that 
will be treated (see the manual of photographic procedures ). Standardized photographs 
must be taken prior to administration of any injection. This photo will serve as the 
baseline photograph. 
 The clinical Investigator will measure the gr id (length and width) corresponding to the 
area of each wrinkle to be treated. 
 Perform initial treatment in accordance with instructions for use (see the Sculptra®  
Aesthetic package insert).  If  a local anesthetic is injected, then the WAS must be 
assessed, after administration of  local anesthetic (prior to injection of Sculptra® 
Aesthetic), and after injecti on of Sculptra® Aest hetic. A maximum of 10 mL (5 mL per 
side of the face), 2 vials of  Sculptra® Aesthetic,  is allowed at each injection session 
and is up to the discretio n of the Investigator. 
 Take post-treatment photographs (see th e manual of photographic procedures). 
 Distribute diary card. 
C
C
I
GALDERMA LABORATORIES, L.P.  Page 48 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  Schedule the subject’s next vi sit in 3 weeks (±3 days). 
 Review subject contact information. 
 
12.1.2 Visit 2 (Week 3)  – second treatment, if needed  
 
The following procedures will be performed (listed in recommended order): 
 All adverse events will be collected including, but not limited to: 
 
- Adverse events of interest: nodule, pa pule, hypertrophic scarring, keloid 
formation, granuloma (confirmed by a biopsy), changes in skin pigmentation, 
skin necrosis, hypersensitivity reacti on, and unexpected changes in wrinkle 
contour 
 
- Adverse events reported in mo re than 1% of subjects duri ng clinical trials regardless 
of relationship to th e device/procedure:  injection-site edema, injection-site 
tenderness, injection-site erythema, injec tion-site pain, inject ion-site bleeding, 
injection-site itching, injec tion-site bruising, injection- site inflammation, injection-
site discomfort, injection-site infection, injection-site acne, injection-site dermatitis, 
and injection-site skin dryness; nasophar yngitis, headache, hypertension, fracture, 
urinary tract infection, tooth abscess, syncope, and cough 
 
- Adverse events reported in less than 1% of subjects during clinical trials regardless 
of relationship to the de vice/procedure: sinusitis, influenza, bronchitis, 
acrochordon, anxiety, colitis, contusi on, corneal abrasion, cyst, depression, 
dermatitis, eczema, gastritis, herpes simplex, hypercholesterolemia, hypersensitivity, hypothyroidism, injecti on site desquamation, injection-site rash, 
lower respiratory infection, lymphadenopat hy, migraine, muscle injury, muscle 
twitching, myalgia, osteoarthritis, osteopenia,  rheumatoid arthritis, gastroenteritis, 
skin burning sensation, spider vein, st aphylococcal infection, stress symptoms, 
tooth infection, toothache,  and vaginal infection 
 
- Adverse events reported during postm arketing surveillance regardless of 
relationship to the device/procedure: a llergic reaction, angioedema (Quincke's 
edema), application site discharge, fatigue , hypersensitivity reaction, hypertrophy of 
skin, injection-site abscess, injection-si te atrophy, injection-site fat atrophy, 
injection-site granuloma (including ectropi on), injection-site induration, lack of 
effectiveness, malaise, periorbital nodules , photosensitivity reaction, scar and skin 
discoloration, skin infection, skin ras h, skin roughness, skin sarcoidosis, 
telangiectasias, and urticarial 
 
 Collect and review the diary card.  Record relevant medica tion use that have occurred 
since the last visit. 
 Subject contact information s hould be reviewed and update d if needed, at each study 
visit and monthly safety contact. 
 Take standardized photogr aphs (see the manual of photographic procedures). 
 The clinical Investigator will visually inspec t the subject’s NLFs and determine severity 
based on the photo-numeric wr inkle assessment scale (see Appendix II ). 
 The clinical Investigator will measur e the length of the subject’s NLFs. 
GALDERMA LABORATORIES, L.P.  Page 49 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  The clinical Investigator will visually insp ect the subject’s other facial wrinkles and 
determine severity based on the Assessment Scale for Other Facial Wrinkles (see 
Appendix III ). 
 The clinical Investigator will measure the leng th of the subject’s other facial wrinkles 
that are planned to be treated. 
 Based on the WAS, the Investigator will dete rmine if further injections of Sculptra® 
Aesthetic are needed; 
 
A treatment session to correct WAS 2 to 4 NLF contour deficiencies consists of multiple 
deep dermal threading or tunneling injection of 0.1 mL to 0.2 mL of  Sculptra® Aesthetic 
in grid pattern to a maximum of 2.5 mL per NLF per session.  Sculptra® Aesthetic 
injections should be stopped when both NL Fs and other facial folds have reached a 
grade of 0 to 1 on the wri nkle assessment scale (see Appendix II and Appendix III). 
Correction should be limited to no more than 100% of the defect. [If only one wrinkle 
has reached the target grade of 0 to 1 the other side should co ntinue to be treated until the 
target grade is achieved (or a maximum of 4 injection sessions a nd a maximum of 2.5 mL 
per NLF per session).] A maximum of 10 mL (5  mL per side of the face), 2 vials of 
Sculptra® Aesthetic, is allowed at each injection session and is up to the discretion of the 
Investigator. 
 
If  the  subject    DOES  NOT require  further  injections:  
 Schedule the three (3 ) month (±2 weeks) follow-up visit from the date of the 
INITIAL treatment (Note: not 3 months from this visit date). 
 Distribute diary card. 
 
If subject DOES require further injections:  
 Note: Only NLFs and other facial wrinkles  treated at Visit 1 may be treated at 
this visit. 
 The clinical Investigator will meas ure the grid (length and width) 
corresponding to the area of each of the wrinkles to be treated. 
 Perform additional injections with Sc ulptra® Aesthetic in accordance with 
instructions for use. NOTE: Photographs must be taken of ea ch area that is 
treated prior to any injection and after administration of Sculptra® Aesthetic 
(see the manual of photog raphic procedures), but not between administration 
of a local anesthetic and Sc ulptra® Aesthetic.  If a lo cal anesthetic is injected, 
then the WAS must be assessed, after admi nistration of local anesthetic (prior 
to injection of Sculptra® Aesthetic), and after inject ion of Sculptra® Aesthetic. 
 Distribute diary card. 
 Subjects will be scheduled  for next visit in thre e (3) weeks (±3 days). 
 
12.1.3 Visit 3 (Week 6)  – third treatment, if needed  
 
The following procedures will be performed (listed in recommended order): 
 All adverse events will be collected including, but not limited to: 
 
GALDERMA LABORATORIES, L.P.  Page 50 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 - Adverse events of interest: nodule, pa pule, hypertrophic scarring, keloid 
formation, granuloma (confirmed by a biopsy), changes in skin pigmentation, 
skin necrosis, hypersensitivity reacti on, and unexpected changes in wrinkle 
contour 
 
- Adverse events reported in mo re than 1% of subjects duri ng clinical trials regardless 
of relationship to the device/procedure: injection-site edema, injection-site 
tenderness, injection-site erythema, injec tion-site pain, inject ion-site bleeding, 
injection-site itching, injec tion-site bruising, injection- site inflammation, injection-
site discomfort, injection-site infection, injection-site acne, injection-site dermatitis, and injection-site skin dryness; nasophar yngitis, headache, hypertension, fracture, 
urinary tract infection, tooth abscess, syncope, and cough 
 
- Adverse events reported in less than 1% of subjects during clinical trials regardless 
of relationship to the de vice/procedure: sinusitis, influenza, bronchitis, 
acrochordon, anxiety, colitis, contusi on, corneal abrasion, cyst, depression, 
dermatitis, eczema, gastritis, herpes simplex, hypercholesterolemia, 
hypersensitivity, hypothyroidism, injecti on site desquamation, injection-site rash, 
lower respiratory infection, lymphadenopat hy, migraine, muscle injury, muscle 
twitching, myalgia, osteoarthritis, osteopenia,  rheumatoid arthritis, gastroenteritis, 
skin burning sensation, spider vein, st aphylococcal infection, stress symptoms, 
tooth infection, toothache,  and vaginal infection 
 
- Adverse events reported during postm arketing surveillance regardless of 
relationship to the device/procedure: a llergic reaction, angioedema (Quincke's 
edema), application site discharge, fatig ue, hypersensitivity reaction, hypertrophy 
of skin, injection-site abscess, injection-site atrophy, injection-site fat atrophy, 
injection-site granuloma (including ectropi on), injection-site induration, lack of 
effectiveness, malaise, periorbital nodules , photosensitivity reaction, scar and skin 
discoloration, skin infection, skin ras h, skin roughness, skin sarcoidosis, 
telangiectasias, and urticaria 
 Collect and review the diary card. Record re levant medication use that have occurred 
since the last visit. 
 Subject contact information should be reviewed and updated if needed, at each 
study visit and monthl y safety contact. 
 Take standardized photo graphs (see the manual of photographic procedures).  
 The clinical Investigator will visually inspect the subject’s NLFs and determine 
severity based on the photo-numeric wrinkle assessment scale (see Appendix II ). 
 The clinical Investigator will measur e the length of the subject’s NLFs. 
 The clinical Investigator will visually in spect the subject’s other facial wrinkles 
and determine severity base d on the Assessment Scale fo r Other Facial Wrinkles 
(see Appendix III ). 
 The clinical Investigator will measure the leng th of the subject’s other facial wrinkles 
that are planned to be treated. 
 Based on the WAS, the Investigator will determine if further injections of 
Sculptra® Aesthetic are needed; 
 
GALDERMA LABORATORIES, L.P.  Page 51 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 A treatment session to correct WAS 2 to 4 NLF contour deficien cies consists of 
multiple deep dermal threading or tunne ling injection of 0.1 mL to 0.2 mL of 
Sculptra® Aesthetic in grid pattern to  a maximum of 2.5 mL per NLF per session. 
Sculptra® Aesthetic injections should be stopped when both NLFs and or other 
facial folds have reached a grade of 0 to 1 on the wr inkle assessment scale (see 
Appendix II and Appendix III ). Correction should be limited to no more than 
100% of the defect. [If only one wrinkle has reached the target grade of 0 to 1 the 
other side should continue to be treated until the target grade is achieved (or a 
maximum of 4 injection sessions and a ma ximum of 2.5 mL per NLF per session).] A 
maximum of 10 mL (5 mL per side of the face), 2 vials of Sc ulptra® Aesthetic, is 
allowed at each injection session and is up to the discretion of  the Investigator. 
 
I f    t h e    s u b j e c t    D O E S   N O T   r e q u i r e         f u r t h e r          i n j e c t i o n s :  
 Schedule the three (3 ) month (±2 weeks) follow-up visit from the date of the 
INITIAL treatment (Note: not 3 months from this visit date). 
 Distribute diary card. 
 
If      subject  DOES  require  further  injections:  
 Note: Only NLFs and other facial wrinkles  treated at Visit 1 may be treated at 
this visit. 
 The clinical Investigator will meas ure the grid (length and width) 
corresponding to the area of each of the wrinkles to be treated. 
 Perform additional injections with Sc ulptra® Aesthetic in accordance with 
instructions for use. NOTE: Photographs must be taken of ea ch area that is 
treated prior to any injection and after administration of Sculptra® Aesthetic 
(see the manual of photog raphic procedures), but not between administration 
of a local anesthetic and Sc ulptra® Aesthetic. If a local anesthetic is injected, 
then the WAS must be assessed, after admi nistration of local anesthetic (prior 
to injection of Sculptra® Aesthetic), and after inject ion of Sculptra® Aesthetic. 
 Distribute diary card.  
 Subjects will be scheduled  for next visit in thre e (3) weeks (±3 days). 
 
12.1.4 Visit 4 (Week 9) – fourth treatment, if needed  
 
The following procedures will be performed (listed in recommended order): 
 All adverse events will be collected including, but not limited to: 
 
- Adverse events of interest: nodule, pa pule, hypertrophic scarring, keloid 
formation, granuloma (confirmed by a biopsy), changes in skin pigmentation, 
skin necrosis, hypersensitivity reacti on, and unexpected changes in wrinkle 
contour 
 
- Adverse events reported in mo re than 1% of subjects duri ng clinical trials regardless 
of relationship to the device/procedure: injection-site edema, injection-site 
tenderness, injection-site erythema, injec tion-site pain, inject ion-site bleeding, 
injection-site itching, injec tion-site bruising, injection- site inflammation, injection-
GALDERMA LABORATORIES, L.P.  Page 52 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 site discomfort, injection-site infection, injection-site acne, injection-site dermatitis, 
and injection-site skin dryness; nasophar yngitis, headache, hypertension, fracture, 
urinary tract infection, tooth abscess, syncope, and cough 
 
- Adverse events reported in less than 1% of subjects during clinical trials regardless 
of relationship to the de vice/procedure: sinusitis, influenza, bronchitis, 
acrochordon, anxiety, colitis, contusi on, corneal abrasion, cyst, depression, 
dermatitis, eczema, gastritis, herpes simplex, hypercholesterolemia, 
hypersensitivity, hypothyroidism, injecti on site desquamation, injection-site rash, 
lower respiratory infection, lymphadenopat hy, migraine, muscle injury, muscle 
twitching, myalgia, osteoarthritis, osteopenia,  rheumatoid arthritis, gastroenteritis, 
skin burning sensation, spider vein, st aphylococcal infection, stress symptoms, 
tooth infection, toothache,  and vaginal infection 
 
- Adverse events reported during postm arketing surveillance regardless of 
relationship to the device/procedure: a llergic reaction, angioedema (Quincke's 
edema), application site discharge, fatig ue, hypersensitivity reaction, hypertrophy 
of skin, injection-site abscess, injection-site atrophy, injection-site fat atrophy, 
injection-site granuloma (including ectropi on), injection-site induration, lack of 
effectiveness, malaise, periorbital nodules , photosensitivity reaction, scar and skin 
discoloration, skin infection, skin ras h, skin roughness, skin sarcoidosis, 
telangiectasias, and urticaria 
 Collect and review the diary card. Record re levant medication use that have occurred 
since the last visit. 
 
 Subject contact information s hould be reviewed and update d if needed, at each study 
visit and monthly safety contact. 
 Take standardized photogr aphs (see the manual of photographic procedures). 
 The clinical Investigator will visually inspec t the subject’s NLFs and determine severity 
based on the photo-numeric wr inkle assessment scale (see Appendix II ). 
 The clinical Investigator will measur e the length of the subject’s NLFs.  
 The clinical Investigator will visually in spect the subject’s other facial wrinkles 
and determine severity base d on the Assessment Scale fo r Other Facial Wrinkles 
(see Appendix III ). 
 The clinical Investigator will measure the leng th of the subject’s other facial wrinkles 
that are planned to be treated. 
 Based on the WAS, the Investigator will determine if further injections of 
Sculptra® Aesthetic are needed; 
 
A treatment session to correct WAS 2 to 4 NLF contour deficien cies consists of 
multiple deep dermal threading or tunne ling injection of 0.1 mL to 0.2 mL of 
Sculptra® Aesthetic in grid pattern to  a maximum of 2.5 mL per NLF per session. 
Sculptra® Aesthetic injections should be stopped when both NLFs and or other 
facial folds have reached a grade of 0 to 1 on the wr inkle assessment scale (see 
Appendix II and Appendix III ). Correction should be limited to no more than 
100% of the defect. [If only one wrinkle has reached the target grade of 0 to 1 the 
other side should continue to be treated until the target grade is achieved (or a 
GALDERMA LABORATORIES, L.P.  Page 53 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 maximum of 4 injection sessions and a ma ximum of 2.5 mL per NLF per session).] A 
maximum of 10 mL (5 mL per side of the face), 2 vials of Sc ulptra® Aesthetic, is 
allowed at each injection session and is up to the discretion of  the Investigator. 
 
I f          t h e        s u b j e c t       D O E S   N O T       r e q u i r e   f u r t h e r   i n j e c t i o n s :  
 Schedule the three (3) month (±2 weeks) follow-up visit from the date of the INITIAL 
treatment (Note: not 3 months from this visit date). 
 Distribute diary card. 
 I f      s u b j e c t   D O E S       r e q u i r e       f u r t h e r   i n j e c t i o n s :  
 Note: Only NLFs and other facial wrinkles treated at Visit 1 may be treated at this 
visit. 
 The clinical Investigator will measure the gr id (length and width) corresponding to the 
area of each of the wr inkles to be treated. 
 Perform additional Sculptra® Aesthetic injections in accordance with instructions for 
use. NOTE: Photographs must be take n of each area that is treated prior to any 
injection and after administration of Sculptra® Aesthetic (see the manual of 
photographic procedures), but not between ad ministration of a local anesthetic and 
Sculptra® Aesthetic.  If a local anesthetic is injected, then the WAS must be assessed, 
after administration of local an esthetic (prior to injection of Sculptra® Aesthetic), and 
after injection of Sculptra® Aesthetic. 
 Distribute diary card. 
 Schedule the three (3) month (±2 weeks) follow-up visit from the date of the INITIAL 
treatment (Note: not 3 months from this visit date).  
 
12.1.5 Follow-up phase 
 
All subjects will be scheduled to  visit the study site at Months 3, 6, 9, 13 (±2 weeks) and Years 2, 
3, 4, 5 (±4 weeks) after the initia l treatment.  In addition, there will be monthly safety contacts 
between each follow-up visit.  Subject contact information will be re viewed and updated as 
needed.  Three contact attempts followed by 2 certified letters will be sent as a reminder contact 
to the subject starting 3 months  before an annual follow-up visit (ie, Years 2, 3, 4, and 5). 
 
All follow-up visit times are relative to the date of the INITIAL treatment.  
 
 
12.1.5.1 Follow-up visits at Month 3, 6, 9, and 13 
 
The following procedures will be performed at the Month 3, 6, 9, and 13 follow-up visits, 
unless specified otherwise: 
 All adverse events will be collected including, but not limited to: 
 
- Adverse events of interest: nodule, papule, hypertrophic scarring, keloid formation, 
granuloma (confirmed by a biopsy), change s in skin pigmentation, skin necrosis, 
hypersensitivity reaction, and unexpected changes in wrinkle contour 
 
GALDERMA LABORATORIES, L.P.  Page 54 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 - Adverse events reported in more  than 1% of subjects during clinical trials regardless of 
relationship to the device/pro cedure: injection-site edema, injection-site tenderness, 
injection-site erythema, injectio n-site pain, injecti on-site bleeding, injection-site itching, 
injection-site bruising , injection-site inflammation, inj ection-site discomfort, injection-
site infection, injection-site acne, injection-site dermatitis, and injection-site skin 
dryness; nasopharyngitis, headache, hypertensi on, fracture, urinary tract infection, tooth 
abscess, syncope, and cough 
 
- Adverse events reported in less than 1% of s ubjects during clinical trials regardless of 
relationship to the device/p rocedure: sinusitis, influenz a, bronchitis, acrochordon, 
anxiety, colitis, contusion, corneal abra sion, cyst, depression, dermatitis, eczema, 
gastritis, herpes simplex, hypercholesterolemia, hypersensitivity, hypothyroidism, 
injection site desquamati on, injection-site rash, lo wer respiratory infection, 
lymphadenopathy, migraine, muscle injury, muscle twitching, myalgia, osteoarthritis, osteopenia, rheumatoid arthritis, gastroente ritis, skin burning sensation, spider vein, 
staphylococcal infection, stress symptoms, tooth infection, toothache, and vaginal infection 
 
- Adverse events reported during postmarketi ng surveillance regardless of relationship 
to the device/procedure: allergic reaction, angioedema (Quincke's edema), application 
site discharge, fatigue, hypersensitivity r eaction, hypertrophy of skin, injection-site 
abscess, injection-site atrophy, injection- site fat atrophy, inje ction-site granuloma 
(including ectropion), injection-site induration, lack of effectiveness, malaise, 
periorbital nodules, photosensitivity reac tion, scar and skin discoloration, skin 
infection, skin rash, sk in roughness, skin sarcoidosis,  telangiectasias,  and urticaria 
 Examine the subject, collect and review diary cards, and review/record relevant medication 
use that has occurred since the last visit (all visits)  
 Take standardized photogra phs (see the manual of photographic procedures) (Months 6 and 
13). 
 The clinical Investigator will visually inspec t the subject’s NLFs and determine severity 
based on the photo-numeric wr inkle assessment scale (see Appendix II ) (Months 6 and 13). 
 The clinical Investigator will measure the leng th of the subject’s NLFs (Months 6 and 13). 
 The clinical Investigator will visually insp ect the subject’s other facial wrinkles and 
determine severity based on the Assessment Scale for Other Facial Wrinkles (Months 6 and 
13) (see Appendix III ). 
 The clinical Investigator will measure the leng th of the subject’s other facial wrinkles 
(Months 6 and 13). 
 Perform Investigator/subj ect global evaluation asse ssments (Months 6 and 13). 
 Subject contact information shou ld be reviewed and updated if  needed, at each study visit 
and monthly safety contact. 
 Distribute diary card. 
 At Months 3, 6, and 9, sche dule next visit (± 2 weeks) ; at Month 13, schedule the 
Year 2 annual vis it (± 4 weeks). 
 For the Months 3, 6, 9, and 13, at least 1 cont act attempt will be made approximately 1 
month prior to the scheduled vi sit as a reminder appointment call (can coincide with the 
GALDERMA LABORATORIES, L.P.  Page 55 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 monthly safety contact) to help ensure compliance. [For the Ye ar 2 annual visit, 3 contact 
attempts followed by 2 certified letters will be sent as a reminder contact to the subject 
starting 3 months before the Year 2 annua l visit to help ensu re compliance (see Section 
12.1.5.2).] 
 Schedule the monthly safety c ontact calls with the subject. 
 
12.1.5.2 Follow-up visits at Years 2, 3, and 4 
 
The following procedures will be performed at the Year 2, 3, and 4 follow-up visits: 
 All adverse events will be collected including, but not limited to: 
 
- Adverse events of interest: nodule, pa pule, hypertrophic scarring, keloid 
formation, granuloma (confirmed by a biopsy), changes in skin pigmentation, 
skin necrosis, hypersensitivity reacti on, and unexpected changes in wrinkle 
contour 
 
- Adverse events reported in mo re than 1% of subjects duri ng clinical trials regardless 
of relationship to the device/procedure: injection-site edema, injection-site 
tenderness, injection-site erythema, injec tion-site pain, inject ion-site bleeding, 
injection-site itching, injec tion-site bruising, injection- site inflammation, injection-
site discomfort, injection-site infection, injection-site acne, injection-site dermatitis, and injection-site skin dryness; nasophar yngitis, headache, hypertension, fracture, 
urinary tract infection, tooth abscess, syncope, and cough 
 
- Adverse events reported in less than 1% of subjects during clinical trials regardless 
of relationship to the de vice/procedure: sinusitis, influenza, bronchitis, 
acrochordon, anxiety, colitis, contusi on, corneal abrasion, cyst, depression, 
dermatitis, eczema, gastritis, herpes simplex, hypercholesterolemia, 
hypersensitivity, hypothyroidism, injecti on site desquamation, injection-site rash, 
lower respiratory infection, lymphadenopat hy, migraine, muscle injury, muscle 
twitching, myalgia, osteoarthritis, osteopenia, rheumatoid arthritis, gastroenteritis, skin burning sensation, spider vein, st aphylococcal infection, stress symptoms, 
tooth infection, toothache,  and vaginal infection 
 
- Adverse events reported during postm arketing surveillance regardless of 
relationship to the device/procedure: a llergic reaction, angioedema (Quincke's 
edema), application site discharge, fatigue , hypersensitivity reaction, hypertrophy of 
skin, injection-site abscess, injection-si te atrophy, injection-site fat atrophy, 
injection-site granuloma (including ectropi on), injection-site induration, lack of 
effectiveness, malaise, peri orbital nodules, photosensitivi ty reaction, scar and skin 
discoloration, skin infection, skin ras h, skin roughness, skin sarcoidosis, 
telangiectasias, and urticaria 
 Examine the subject, collect and review diary card, and review/record relevant 
medication use that have occurred since the last  visit (all visits). 
 Take standardized photogr aphs (see the manual of photographic procedures). 
 The clinical Investigator will visually inspect the subject’s NLFs and determine 
severity based on the photo-numeric wrinkle assessment scale (see Appendix II ). 
GALDERMA LABORATORIES, L.P.  Page 56 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  The clinical Investigator will measur e the length of the Subject’s NLFs. 
 The clinical Investigator will visually insp ect the subject’s other facial wrinkles and 
determine severity based on the Assessment Scale for Other Facial Wrinkles (see 
Appendix III ). 
 The clinical Investigator will measure the leng th of the subject’s other facial wrinkles. 
 Perform Investigator/subj ect global evaluation as sessments (all visits). 
 Subject contact information s hould be reviewed and update d if needed, at each study 
visit and monthly safety contact. 
 Distribute diary cards. 
 Schedule the next a nnual visit (±4 weeks) from the date of the initial tr eatment.  Three 
contact attempts followed by 2 certified letter s will be sent as a reminder contact to the 
subject starting 3 months before an annual follow-up visit to help ensure compliance. 
These can coincide with th e monthly safety contact. 
 Schedule the monthly safety contacts with the subject. 
 
 
12.1.5.3 End of study or early termination visit (Year 5) 
 
The following procedures will be performed at Year 5, end of study or early termination visit:  
 All adverse events will be collected including, but not limited to:  
 
- Adverse events of interest: nodule, pa pule, hypertrophic scarring, keloid 
formation, granuloma (confirmed by a biopsy), changes in skin pigmentation, 
skin necrosis, hypersensitivity reacti on, and unexpected changes in wrinkle 
contour 
 
- Adverse events reported in mo re than 1% of subjects duri ng clinical trials regardless 
of relationship to the device/procedure: injection-site edema, injection-site tenderness, injection-site erythema, injec tion-site pain, inject ion-site bleeding, 
injection-site itching, injec tion-site bruising, injection- site inflammation, injection-
site discomfort, injection-site infection, injection-site acne, injection-site dermatitis, and injection-site skin dryness; nasophar yngitis, headache, hypertension, fracture, 
urinary tract infection, tooth abscess, syncope, and cough 
 
- Adverse events reported in less than 1% of subjects during clinical trials regardless 
of relationship to the de vice/procedure: sinusitis, influenza, bronchitis, 
acrochordon, anxiety, colitis, contusi on, corneal abrasion, cyst, depression, 
dermatitis, eczema, gastritis, herpes simplex, hypercholesterolemia, 
hypersensitivity, hypothyroidism, injecti on site desquamation, injection-site rash, 
lower respiratory infection, lymphadenopat hy, migraine, muscle injury, muscle 
twitching, myalgia, osteoarthritis, osteopenia,  rheumatoid arthritis, gastroenteritis, 
skin burning sensation, spider vein, st aphylococcal infection, stress symptoms, 
tooth infection, toothache,  and vaginal infection 
 
- Adverse events reported during postm arketing surveillance regardless of 
relationship to the device/procedure: a llergic reaction, angioedema (Quincke's 
GALDERMA LABORATORIES, L.P.  Page 57 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 edema), application site discharge, fatig ue, hypersensitivity reaction, hypertrophy 
of skin, injection-site abscess, injection-site atrophy, injection-site fat atrophy, 
injection-site granuloma (including ectropi on), injection-site induration, lack of 
effectiveness, malaise, periorbital nodules , photosensitivity reaction, scar and skin 
discoloration, skin infection, skin ras h, skin roughness, skin sarcoidosis, 
telangiectasias, and urticaria 
 Examine the subject, collect and review diary card, and review/record relevant 
medication use that have occurred since the last visit. 
 Take standardized photogr aphs (see the manual of photographic procedures). 
 The clinical Investigator will visually inspect the subject’s NLFs and determine 
severity based on the photo-numeric wrinkle assessment scale (see Appendix II ). 
 The clinical Investigator will measur e the length of the subject’s NLFs. 
 The clinical Investigator will visually insp ect the subject’s other facial wrinkles and 
determine severity based on the Assessment Scale for Other Facial Wrinkles (see 
Appendix III ). 
 The clinical Investigator will measure the leng th of the subject’s other facial wrinkles. 
 Perform Investigator/sub ject global evaluation assessments (all visits).  
 Final subject study status information is collected and all necessary study related  
documentation is completed. 
 The subject will be discha rged from the study. 
 
12.2 MONTHLY SAFETY CONTACTS 
 
During the follow-up phase (Month 3 through Year  5), the site personnel will contact each 
subject monthly to review/record  adverse events that have oc curred and relevant medication 
that were taken since the last site visit, as  well as confirm the ne xt follow-up visit. The 
monthly safety contact and reminder contact will occur at the same time, whenever possible. In 
the event an adverse event is recorded that is listed in Section 9.1.1 (Primary safety criteria), 
the subject will be brought in  for an unscheduled visit. 
 
Subject contact information should  be reviewed and updated if need ed.  If the site is unable 
to contact the subject directly within 3 months before each of  their annual follow-up visits, 
the site will attempt to make 3 attempts to co ntact the subject, followed by 2 certified letters. 
 
12.3 UNSCHEDULED VISITS 
 
In the event that an ad verse event listed in Section 9.1.1 (Primary safety criteria) occurs, the 
subject will be brought in for an unscheduled visit, a photogra ph will be taken (see the manual 
of photographic procedures), and the subject will then receive  monthly safety contacts until 
resolution or stabilization (no further changes expected) of th e adverse event. Upon resolution 
or stabilization of the adverse event, the subj ect will return for a follow-up unscheduled visit 
for verification of the resolution or stabilization of the effect by the Investigator. The resolution 
of the adverse event will be  documented on the source docu ments and on the adverse event 
CRF. 
GALDERMA LABORATORIES, L.P.  Page 58 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
12.4 EARLY TERMINATION 
 
If a subject is withdrawn before  the end of the study the followi ng procedures, in addition to 
those listed in Section 12.1.5.3, will be performed during an early termination visit (listed in 
recommended order): 
 Determine and record reason for early term ination and initiate plan for follow-up 
(see Section 11.2.2 Handling of subjects after defi nitive treatment discontinuation 
and Section 11.3 Procedures for withdrawal of subjects from study follow-up 
schedule). 
 Complete all necessary study documentati on as well as end of study completion 
page of the CRF. 
 
12.5 DEFINITION OF SOURCE DATA 
 
The data source for the analyses of the pr imary and secondary endpoints will be medical 
records and the study specific source documents for the study. Source data will be where 
the information is first recorded at the investigative site. 
 
 
13 STATISTICAL CONSIDERATIONS 
 
13.1 STATISTICAL AND ANALYTICAL PLANS 
 
The material of Section 13 of the clinical trial protocol is the basis for the statistical analysis 
plan for the study. This plan may be revised during the study to accommodate clinical trial 
protocol amendments and to make changes to adapt to unexpected issu es in study execution 
and data that affects planned analysis. These re visions will be based on a review of the study 
data, and a final plan will be i ssued before database lock. Complete details of the statistical 
analyses and methods, including data conventions , will be contained in a separate and final 
statistical analysis plan. 
 
 
13.2 DETERMINATION OF SAMPLE SIZE 
CCI
GALDERMA LABORATORIES, L.P.  Page 59 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 13.3 ANAL
YSIS VARIABLES 
 
 
13.3.1 Demographic and baseline characteristics 
 
Demographic and baseline charac teristics include subjects’ sex, race/ethnicity, age, 
height, weight, medical history, prior and co ncomitant medications, length of NLFs and 
other facial wrinkles, and vital signs (s itting heart rate a nd blood pressure). 
 
 
13.3.2 Safety variables 
 
 
13.3.2.1 Adverse events 
 
The co-primary safety endpoints are: 
 
1.   The percentage (incidence rate) of s ubjects with any injecti on site nodule and/or 
papule over 5 years. 
 
2.   The percentage (incidence rate) of subj ects with any of the following injection site 
events over 5 years: 
 Hypertrophic scarring 
 Keloid formation 
 Changes in the skin pigmentation at the site  of injection compared to adjacent skin 
 Granuloma (confirmed by a biopsy) 
 Skin necrosis 
 Hypersensitivity reactions 
 Unexpected change in wrinkle contour 
CCI
GALDERMA LABORATORIES, L.P.  Page 60 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
The injection site adverse events  listed above are defined as a dverse events of interest in 
this study. 
 
The secondary safety endpoints are the percenta ges (incidence rate) of subjects with any 
injection site nodule and/ or papule, the percentage of subj ects who experienced any adverse 
events of interest other than  nodule or papule over 2 years; location and intervention for any 
adverse events of interest; adverse event severi ty, duration, time to ons et of adverse event, 
relationship to Sculptra ® Aesthetic and relations hip to injection proce dure during the course 
of the study. 
 
 
13.3.2.2 Laboratory safety variables 
 
A urine pregnancy test for women of child-b earing potential will be collected at Visit 1. 
13.3.2.3 Vital signs and physical exam 
 
Vitals signs (sitting heart rate  and blood pressure) and physic al examination (overall subject 
assessment and facial assessment) will only be collected at Visit 1 and considered as the 
baseline characteristics for each subject (see Section 13.3.1). 
 
 
13.3.2.4 Other safety variables 
 
None. 
 
 
13.3.3 Efficacy variables 
 
 
13.3.3.1 Primary efficacy variables 
 
None. 
 
 
13.3.3.2 Secondary efficacy variables 
 
The secondary efficacy endpoints are: 
 Change from baseline to post-treatment  follow-up time points in the WAS at 
Month 6, Month 13, and Years 2, 3, 4, and 5. 
 Investigator/Subject Global Assessments Scores at Month 6, Month 13, and Years 
2, 3, 4, and 5. 
 
 
13.4 ANALYSIS POPULATIONS 
 
The intent-to-treat (ITT) popul ation, per protocol (PP) popul ation, and Completer2 and 
Completer5 populations are defined as follows: 
 
GALDERMA LABORATORIES, L.P.  Page 61 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
13.4.1 Efficacy populations 
 
The analysis populations for efficacy will be th e ITT population that consists of all subjects 
who receive at least one Sculpt ra® Aesthetic injecti on; the PP population will consist of all 
subjects who receive at least 1 Sculptra® Aesthetic injecti on and are without any major 
protocol deviation. 
 
 
13.4.2 Safety populations 
 
The analysis population for safety will also include the ITT populati on and the PP population. 
The ITT population is the primary pop ulation for hypothesis testing. 
 
 
13.4.3 Other analysis populations 
 
The Completer2 population consists  of all subjects who receive at least 1 Sculptra® Aesthetic 
injection and finish the second year visit.   
The Completer5 population consis ts of all subjects who re ceive at least 1 Sculptra® 
Aesthetic injection and fini sh the fifth year visit. 
 
 
13.4.4 Disposition of subjects 
 
The general disposition of subjects during the study will be defined as follows: (a) screened 
subjects are those who have a writ ten informed consent document; (b) treated subjects are 
those screened subjects who re ceived at least 1 dose of Sc ulptra® Aesthetic; and (c) completed 
subjects are those treated subjec ts who complete all clinical trial protocol required visits. 
 
 
13.5 STATISTICAL METHODS 
 
13.5.1 Demographics and baseline characteristics 
 
Demographics and baseline charac teristics will be summarized by  descriptive statistics, which 
consist of mean, standard deviation, median, minimum and maximum for continuous 
variables or frequency c ount and percentage for categorical variables. 
 
 
CCI
GALDERMA LABORATORIES, L.P.  Page 62 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 13.5.2 Extent of study treatment exposure and compliance 
 
Extent of treatment exposure and compliance wi ll be determined by the number of injection 
sessions, duration of treatment pe riod (days), the total amount of Sculptra® Aesthetic used, the 
total amount of Sculptra® Aest hetic used per inje ction site and the amount of Sculptra® 
Aesthetic used per surface area per WAS. They will all be summarized by descriptive statistics. 
 
 
13.5.4 Anal
ysis of safety data 
 
CCI
CCI
GALDERMA LABORATORIES, L.P.  Page 63 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 
CCI
GALDERMA LABORATORIES, L.P.  Page 64 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
13.5.4.2 Other analyses of adverse events 
 
All adverse events will be collected and summarized with the number of subjects reporting 
adverse events by number of in jections, system organ class, preferred term, severity, and 
relationship to the Sculpt ra® Aesthetic or injectio n procedure as well. Time to onset of the first 
adverse event of interest  and the duration of ad verse event of interest (maximum duration if 
there are multiple adverse events of interest with a subject) will be summarized by Kaplan-
Meier plots. 
 
Treatment-emergent adverse events (TEAEs) are defined as adverse even ts that develop or 
worsen during the on-treatment period (time from first dose of Sculptra® Ae sthetic to the end of 
the study). All adverse events will be c oded using the current version of MedDRA. 
 The following frequency distributio ns of adverse events (inciden ce tables) will be provided: 
 Overview of adverse events 
 All TEAEs by number of injections 
 All TEAEs by system organ class and preferred term 
 All TEAEs by system organ class and pr eferred term by decreasing frequency 
 All TEAEs by preferred term by decreasing frequency 
 All TEAEs by system organ class, preferred term and intensity 
 Possibly related TEAEs by system organ class, preferred term and intensity 
 
The following listings will be pr ovided for the ITT population: 
 All adverse events 
 Serious adverse events 
CCI
GALDERMA LABORATORIES, L.P.  Page 65 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  adverse events that resulted in death 
 adverse events that lead to disc ontinuation of Scul ptra® Aesthetic 
 Nodules and papules 
 adverse events of interest , other than nodule and papule 
 
 
13.5.4.3 Laboratory variables analysis 
 
Not applicable. 
 
13.5.4.4 Analysis of vital sign variables 
 
Not applicable. 
 
 
13.5.4.5 Analysis of other safety variables 
 
Not applicable. 
 
 
13.5.4.6 Analysis of pharmacokinetic and pharmacodynamic variables 
 
Not applicable. 
 
 
13.5.4.7 Analysis of health economics variables 
 
Not applicable. 
 
 
13.6 INTERIM ANALYSIS 
 
Interim analyses will be conducted on all study variables at 4 time points: 
 Following completion of all subjects Month 13 follow-up visits; 
 Following completion of all subjects Year 2 follow-up visits; 
 Following completion of all subject s Year 3 follow-up visits; and 
 Following completion of all subjects Year 4 follow-up visits. 
 
For each interim analysis the method of analys is will be the same as  described above in 
Section 13.5 .  
 
  
CCI
GALDERMA LABORATORIES, L.P.  Page 66 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
13.7 MISSING DATA 
 
The following rules will be a pplied to handle missing data  in the safety analyses: 
 If a subject discontinues the study before 5 ye ars, all his/her safety information before 
discontinuation will be used in the safety an alysis, and the subject will be assumed to 
have no adverse events betwee n the date of discontinuati on and the 5-year timepoint. 
Sensitivity analyses for primary and sec ondary hypotheses will be conducted as 
described in Section 13.5.4.1. 
 If the timing of an adverse event cannot be  identified because of missing data and the 
subject is treated, the adverse event will be considered as a TEAE. 
 If the assessment of the intensity is missing, the most severe case will be assumed in the 
frequency tables of a dverse event intensity. 
 If the assessment of the relationship to the Sculptra® Aesthetic or injection procedure is 
missing, a possible relationshi p to the Sculptra® Aesthetic will be assumed in the 
frequency tables of possibly related adverse events. 
 
Detailed plans for handling missing data will be contained in the statistical analysis plan. 
 
14 ETHICAL AND REGULATORY STANDARDS 
 
 
14.1 ETHICAL PRINCIPLES 
 
This clinical trial will be conducted in accordan ce with the principles laid down by the 18th 
World Medical Assembly (Helsink i, 1964) and all applicable am endments laid down by the 
World Medical Assemblies and the Intern ational Conference on Harmonization (ICH) 
guidelines for Good Clinical Practice. 
 
14.2 LAWS AND REGULATIONS 
 
This clinical trial will be conducted in compliance with all interna tional laws and regulations, and 
national laws and regulati ons of the country in wh ich the clinical trial is  performed, as well as 
any applicable guidelines. 
 
 
14.3 INFORMED CONSENT 
 
The Investigator (according to applicable regula tory requirements), or a person designated by 
the Investigator, and unde r the Investigator’s responsibility, should fully inform the subject of 
all pertinent aspects of the clinical tria l including the writte n information giving 
approval/favorable opinion by the IR B. All participants should be informed to the fullest extent 
possible about the study, in language and terms they are able to understand. 
 
GALDERMA LABORATORIES, L.P.  Page 67 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 Prior to a subject’s participation in the clinical trial, the written informed consent form and any 
other local applicable documents in accordance  with local laws and regulations, should be 
signed, name filled in and personally dated by the subject and by the person who conducted the 
informed consent discussion. Copi es of the signed and dated written informed consent form 
will be provided to the subject. 
 
The informed consent form used by the Inves tigator for obtaining the subject’s informed 
consent must be reviewed and approved by the Sponsor or designee prior to submission to the 
appropriate IRB for appr oval/favorable opinion. 
 
To encourage continued participation, subjects may be pr ovided with a m odest financial 
compensation to help defray the associated expenses (eg, transportation to the trial site). 
14.4 INSTITUTIONAL REVIEW BOARD (IRB) 
 
The Investigator or the Sponsor/designee must submit this clinical trial protocol to the 
appropriate IRB, and is require d to forward to the Sponsor/des ignee a copy of the written and 
dated approval/favorable opinion signed by the chairman with IRB composition. 
 
The clinical trial (study code, clinical trial protocol title and version number), the documents 
reviewed (clinical trial protoc ol, informed consent form, package insert, Investigator’s 
curriculum vitae, etc.), the lis t of voting members and their qua lifications, and th e date of the 
review should be clearly stated on th e written IRB approv al/favorable opinion. 
 Sculptra® Aesthetic and SWFI will not be released  to the study site and the clinical trial will 
not start until a copy of this written and dated approval/favorab le opinion has been received by 
the Sponsor or designee. 
 
During the clinical trial, any am endment or modification to the c linical trial protocol should be 
submitted to the IRB. It should also be informed of any effect likely to affect the safety of 
subjects or the continued conduct of the clinical trial, in partic ular any change in safety. All 
updates to the package insert will be sent to the IRB. 
 If requested, a progress repor t will be sent to the IRB annually and a summary of the 
clinical trial’s outcome at the end of the clinical trial. 
 
15 STUDY MONITORING 
 
 
15.1 RESPONSIBILITIES OF THE INVESTIGATOR(S) 
 
The Investigator(s) undertake(s) to perform the c linical trial in accordan ce with this clinical 
trial protocol, ICH guidelines  for Good Clinical Practice an d the applicable regulatory 
requirements. The Investigator  will ensure the accuracy, completeness, legibility, and 
timeliness of the data re ported to the Sponsor/designee in th e CRFs and in all required reports, 
as per ICH-E6. 
GALDERMA LABORATORIES, L.P.  Page 68 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confide ntial, proprietary information. 
 
 
The Investigator may provide each subject wi th “A Patient’s Guide to Treatment with 
Sculptra® Aesthetic,” to resolve any s ubject questions after the subj ect has read this guide and 
to ensure compliance with all procedures required by the clinical trial protocol and with all 
study procedures provided by th e Sponsor (including security rule s). The Investigator agrees to 
provide reliable data and all information requested by the clinical trial protocol (with the help 
of the CRF, discrepancy resolution form [DRF] or other appropriat e instrument) in an accurate 
and legible manner according to the instructions pr ovided, and to ensure direct access to source 
documents by Sponsor representatives. 
 
The Investigator may appoint a designee or such other individuals as he/she may deem 
appropriate as subinvestigators to assist in the co nduct of the clinical  trial, including 
transcription of source data , in accordance with the clinical trial protocol. All 
subinvestigators shall be appoint ed and listed in a timely manne r. The subinvestigators will 
be supervised by and under the  responsibility of the Investigator. The Investigator will 
provide them with a copy of the clinical tr ial protocol and all ne cessary information. 
 
The Investigator must maintain the clinical trial documents as requi red by the applicable 
regulatory requirements (see Section 16.2 ). The Investigator must take measures to 
prevent accidental or premature destruc tion of these documents (see Sections 15.3 and 
16.2). 
 
Contact prior to annual visits  
 
Before a subject is considered lost-to-follow-up,  the Investigator will attempt to contact the 
subject 3 times followed by 2 certified letter s starting 3 months before an annual follow-up 
visit (ie, Years 2, 3, 4, and 5) (see Sections 12.1.5 and Section 12.2). If still unable to contact 
the subject, the site will contact the subject’s re lative/next of kin or s earch National databases 
(ie, those at the time of signing informed consent) as shown in the Figure 2.  
 
 
Figure 2 - Steps to be taken before a subject is considered to be lost-to-follow-up  
 
Subject contact information should be reviewed and updated if needed, at each study visit and monthly safety 
contact.  
 
Three weekly calls (to subject/next of kin) beginning one week after the missed visit window 
(using current telephone number/s provided during the study).  All attempts to contact the 
subject should be recorded in the source document. 
 
 
No response  
 
 
Two certified letters to be sent in two week intervals after the last phone attempt (using 
subject’s current address provided during the study).  All attempts to contact the subject should be recorded in the source document. 
 
 
Note:  If permitted by subject and by local laws and regulations, a national database could be 
searched to determine survival status. 
GALDERMA LABORATORIES, L.P.  Page 69 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
 
15.2 RESPONSIBILITIES OF THE SPONSOR 
 
The Sponsor of this clin ical trial is responsible to health authorities for taking all reasonable 
steps to ensure the proper conduc t of the clinical trial protocol as regards ethics, clinical trial 
protocol compliance, and integrity and validity of the data recorded on the CRFs. Thus, the 
main duty of the monitoring team is to help th e Investigator and the S ponsor maintain a high 
level of ethical, scientific, technical, and regulatory quality in all aspects of the clinical trial. 
 
At regular intervals during the clinical trial, th e site will be contacted, through monitoring visits, 
letters, and/or contacts, by a re presentative of the monitoring t eam to review study progress, 
Investigator and subject compliance with clinical  trial protocol requirements and any emergent 
problems. During these monitoring visits, the follo wing, but not exhaustive, list of points will be 
scrutinized with the Investigator: subject in formed consent, subject eligibility, subject 
recruitment and follow-up, seri ous adverse event documentatio n and reporting, Sculptra® 
Aesthetic and SWFI allo cation, subject compliance with the clinical trial protocol and the 
Sculptra® Aesthetic /SWFI re gimen, Sculptra® Aesthetic and SWFI accountability, 
concomitant therapy use,  and quality of data. 
 
The Sponsor will ensure that all participating Investigators are successfully trained on the use 
of Sculptra® Aesthetic, which includes WAS us e, grid (cross-hatch) and a description of 
injection technique for NLFs and other facial wrinkles , as allowed by this  protocol, and for 
which grid (cross-hatch) injection is clinically appropriate. 
 
 
15.3 SOURCE DOCUMENT REQUIREMENTS 
 
According to the ICH guidelines for Good Clini cal Practice, the monito ring team must check 
the CRF entries against the source documents,  except for the pre-identified source data 
directly recorded in the CRF. The informed c onsent form will include a statement by which 
the subject allows the Sponsor’s duly authorized personnel, the IRB, and the regulatory 
authorities to have direct ac cess to source data which s upport the data on the CRFs (eg, 
subject’s medical file, appointment books, original laboratory records, etc.). Such personnel, bound by professional secrecy, must keep co nfidential all personal identity or personal 
medical information (according to confidentiality rules). 
 
 
15.4 USE AND COMPLETION OF CASE REPORT FORMS AND ADDITIONAL 
REQUEST 
 
It is the responsibility of the Investigator to ma intain adequate and accurate CRFs (according to 
the technology used) designed by  the Sponsor to record (accordi ng to Sponsor instructions) all 
observations and other data pertinent to the clin ical investigation.  The sites will be provided a 
CRF Completion Guideline with detailed instructi ons on when and how to complete all aspects 
GALDERMA LABORATORIES, L.P.  Page 70 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 of the CRF. Data can be entered into the electronic  CRFs by any member of  the site staff who is 
clearly identified on the Delega tion of Duties form, and who: 
 
 Has successfully completed CRF trai ning provided by the Sponsor, and 
 
 Has an individual acce ss code and password. 
 
 
15.5 USE OF COMPUTERIZED SYSTEMS 
 
SAS will be used for statistical analysis. The data management system will be determined once 
the data management ven dor has been identified. 
 
16 ADMINISTRATIVE RULES 
 
 
16.1 CURRICULUM VITAE 
 
An updated copy of the curriculum vitae limited to  the experience, qualifications, and training for 
each Investigator and subinvestig ator will be provided to the S ponsor or designee prior to the 
beginning of the clinical trial. 
 
 
16.2 RECORD RETENTION IN STUDY SITE(S) 
 
The Investigator must maintain confidentia l all study documentation, and take measures 
to prevent accidental or prematur e destruction of these documents. 
 
The Sponsor will inform the investigator of the tim e period for retaining the site records in order 
to comply with all applicable regulatory require ments. The minimum retention time will meet the 
strictest standard applicable to a particular site, as dictated by local laws/regulations, Sponsor 
standard operating procedures, a nd/or institutional requirements. 
 
The Investigator must notify the Sponsor prior to destroying any essential study 
documents following completion or disc ontinuation of the clinical trial. 
 If the Investigator’s personal situation is such  that archiving can no longer be ensured by 
him/her, the Investigator shall inform the Sponsor  and the relevant records shall be transferred 
to a mutually agreed upon designee. 
 
 
17 CONFIDENTIALITY 
 
All information disclosed or provided by th e Sponsor (or any company/institution acting on 
their behalf), or produced during th e clinical trial, including, but not limited to, the clinical trial 
GALDERMA LABORATORIES, L.P.  Page 71 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 protocol, the CRFs, the Packag e insert and the results obtained during the course of the 
Clinical Trial, is confidential.  The Investigator and any person under his/her authority agree to 
undertake to keep confidential a nd not to disclose the informa tion to any third party without 
the prior wri tten approval of  the Sponsor. 
 
However, the submission of this clinical trial pr otocol and other necessary  documentation to the 
IRB is expressly permitted, the IRB members ha ving the same obligatio n of confidentiality. 
 The subinvestigators shall be bound by the same obligation as the Investigator. The 
Investigator shall inform the subinvestigators of the confidential nature of the clinical trial. 
 
The Investigator and the subinvest igators shall use the information solely for the purposes of the 
clinical trial, to the exclusion of any us e for their own or for a third party’s account. 
 
18 PROPERTY RIGHTS 
 
All information, documents, and Sculptra® Aesthe tic provided by the Spon sor or its designee 
are and remain the sole property of the Sponsor. 
 
The Investigator shall not mention any info rmation or the Sculpt ra® Aesthetic in any 
application for a patent or for any other intellectual property rights. 
 All the results, documents  and inventions, which ar ise directly or indirectly from the clinical 
trial in any form, shall be the exclusive property of the Sponsor. 
 The Sponsor may use or exploit all the results at its own discretion, without any limitation to 
its property right (territory, field, continuan ce). The Sponsor shall be under no obligation to 
patent, develop, market or otherwise use the results of the clinical trial. 
 
19 DATA PROTECTION 
 
Each subject’s personal data and Investigator’s  personal data which may be included in the 
Sponsor database shall be treated in complianc e with all applicable laws and regulations. 
 
When archiving or processing person al data pertaining to the Invest igator and/or to the subjects, 
the Sponsor shall take a ll appropriate measures to safeguard and prevent access to  this data by 
any unauthorized third party. 
 
  
GALDERMA LABORATORIES, L.P.  Page 72 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 20 SPONSOR AUDITS AND IN SPECTIONS BY REGULATORY 
AGENCIES 
 
For the purpose of ensuring compliance with the c linical trial protocol, Good Clinical Practice 
and applicable regulatory requirements, the I nvestigator should perm it auditing by or on the 
behalf of the Sponsor and inspection by applicable regulatory authorities. 
 
The Investigator agrees to allow the auditors/in spectors to have direct access to his/her study 
records for review, being understood that their personnel are bound by prof essional secrecy, and 
as such will not disclose any personal identity or personal medical information. 
The Investigator will make ev ery effort to help with the performance of the audits and 
inspections, giving access to all necessary facilities, data, and documents. 
 
As soon as the Investigator is notified of a future inspection by the aut horities, he/she will 
inform the Sponsor and authorize the Spons or to participate in this inspection. 
 The confidentiality of the da ta verified and the protection of the subjects should be 
respected during th ese inspections. 
 Any result and information arising from the insp ections by the regulatory authorities will 
be immediately communicated by th e Investigator to the Sponsor. 
 The Investigator shall take appropriate m easures required by the Sponsor to take 
corrective actions for all problems fo und during the audit or inspections. 
 
21 PREMATURE DISCONTINU ATION OF THE STUDY OR 
PREMATURE CLOSE-OUT OF A SITE 
 
21.1 DECIDED BY THE SPONSO R IN THE FOLLOWING CASES 
 
 
 If the information on the product leads to doubt as to  the benefit/risk ratio; 
 If the Investigator has received from th e Sponsor all Sculptra ® Aesthetic and SWFI, 
means and information necessary to perfor m the clinical trial and has not included 
any subject after a reasonable period of time mutually agreed upon; 
 In the event the results of the clinical trial do not appear to  be scientifically convincing 
to the Sponsor (for example, based on th e results of a planne d futility analysis); 
 If the aim of the clinical trial has become outdated or is no longer of interest; 
 In the event of breach by the Investigator of a fundamental obligation under this 
agreement, including but not limited to breach of the clinical trial protocol, breach of 
the applicable laws and regula tions or breach of the ICH guidelines for Good Clinical 
Practice; 
 If the total number of subjects are included earlier than expected. 
GALDERMA LABORATORIES, L.P.  Page 73 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  In any case the Sponsor will notify the Invest igator of its decision by written notice. 
 
 
21.2 DECIDED BY THE INVESTIGATOR 
 
The Investigator must notify (at least 30 days  prior to discontinua tion) the Sponsor of 
his/her decision and give the reason in writing. 
 
In all cases (decided by the Sponsor or by the Investigator), the appropriate IRB and 
health authorities should be informed. 
 
22 CLINICAL TRIAL RESULTS 
 
The Sponsor will be responsible for preparing a clinical study report. 
 When the data from all inves tigational sites have been full y analyzed by the Sponsor, the 
latter will communicate the results of the c linical trial to the Investigator(s). 
 Regardless of the study outcome, the Sponsor  is committed to publishing the results. 
 
23 PUBLICATIONS AND COMMUNICATIONS 
 
23.1 PUBLICATION/COMMUNICATION OF STUDY RESULTS 
 
The Sponsor recognizes the Investigator’s right to  utilize data derived fr om the clinical trial 
for teaching purposes, communication at co ngresses and scientific publications. 
Nevertheless, in order to ensure  the accuracy and scientific value of the information, while 
preserving the independence and accountability of the Investigator, and the confidentiality of 
the information, only checked and validated data will be used. To that effect, it is essential 
that the parties exchange and discuss, prior to any publicat ion or communication, any draft 
publication or communication ma de by the Investigator. 
 
The Investigator shall send to the Sponsor a copy of the manuscript for review and possible 
comments at least forty-five (45)  calendar days in advance of the date of submission to the 
journal and at least twen ty (20) days in advance for abstra cts. The publication shall be delayed 
until a written response is received  by the Sponsor, not to exceed ninety (90) days. The Sponsor 
can delay publication or communica tion for a limited time in order to protect the confidentiality 
or proprietary nature of any information contained therein, it being understood that the Sponsor 
cannot refuse its consent without  reasonable cause. The Investigator agrees to include the 
modifications requested by  the Sponsor, provided they do not jeopardize the accuracy and/or the 
scientific value of  the publication. 
 All study Investigators and committee members gi ve full authority to the Steering Committee, 
if applicable, for primary presentation and/or primary publication of results. However, in the 
GALDERMA LABORATORIES, L.P.  Page 74 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 absence of primary publication with in 12 months of the termination of the clinical trial at all 
other sites, the Sponsor or the Steering Co mmittee, if applicable, may consider the 
Investigator’s request for indepe ndent publication. The Investig ator agrees not to publish the 
results of the clinical trial pertaining to his/ her center prior to the publication of the overall 
clinical trial results. If no publication has occurred  within twelve (12) months of the termination 
of the clinical trial at all other sites, th e Investigator shall ha ve the right to publish 
independently the results of this clinical trial, su bject to the review proced ure set forth herein. If 
the clinical trial is conducted with the support of a Steering Co mmittee, the latter may define 
specific rules for publication. 
 
No other publication is allowed before the primary publication. An y subsequent presentation or 
publication by a study participant (including for sub studies) must  be reviewed by the Sponsor 
and make reference to the study  and the primary publication. 
The Investigator shall not use the name(s) of the Sponsor and/or it s employees in advertising or 
promotional material or publi cation without the pr ior written consent of the Sponsor. The 
Sponsor shall not use the name(s) of the Investigator and/or the collaborators in advertising or 
promotional material or publicat ion without having received his/ her and/or their prior written 
consent(s). 
 
The Sponsor has the right at any time to pub lish the results of th e clinical trial. 
 
23.2 PUBLIC DISCLOSURE OF CLINICAL TRIALS 
 
Regarding clinical trial registries, the Sponsor will comply with the following: 
 This clinical trial will be r ecorded in a registry accessible to the public free of charge; 
the Sponsor has decided to register its clinical trials on th e following Web site: 
www.clinicaltrials.gov. 
 
- The registry will contain basic informa tion about each trial sufficient to 
inform interested subjects (and their h ealthcare practitioners) how to enroll 
in the trial; 
 
- The trial will be registered under a unique identification number to 
ensure transparency of clinical trial results; 
 
- As a general rule, clinical trial information will be published within 21 
days following enrollment of the first subject. 
 
- If trial results are publishe d in a peer-reviewed medical  journal, the database 
will contain a citation to or link to the journal article and/or a summary of the 
results in a standard format, such as the ICH E-3 summary format, that includes 
a description of th e trial design and methodology , results of primary and 
secondary outcome measures, and safety results. Study results will be recorded 
in a database in the ICH E-3 format if they are not published in a medical 
journal within the required time frame. 
 
GALDERMA LABORATORIES, L.P.  Page 75 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 - Results will include the unique identi fication number used to register 
the corresponding trial. 
 
- As a general rule, results will be publishe d within one year of trial completion, 
unless such publication would compromi se publication in a peer-reviewed 
medical journal or contravene national laws or regulations. 
 
In case of local requirement, addi tional registration at local regi stries may also be done by the 
Sponsor. 
 
 
24 CLINICAL TRIAL PROTOCOL AMENDMENTS 
 
All appendices attached here to and referred to herein are made pa rt of this clinical trial protocol.  
The Investigator should not impl ement any deviation from, or ch anges in, the c linical trial 
protocol without agreement by  the Sponsor, approval by th e FDA and prior review and 
documented approval/favorable op inion from the IRB of an amendment, except where necessary 
to eliminate an immediate hazard(s) to clinical trial subjects, or when the change(s) involves only 
logistical or administra tive aspects of the trial. Any chan ge agreed upon will be recorded in 
writing, the written amendment will be signed by  the Investigator and by the Sponsor, and the 
signed amendment will be filed with this clinical trial protocol.  
Any amendment to the clinical trial protocol re quires written approval/favorable opinion by the 
FDA and the IRB prior to its implementation, un less there are overriding safety reasons. 
 
In some instances, an amendment may require a change to the inform ed consent form. The 
Investigator must receive an IRB approval/favor able opinion concerning the revised informed 
consent form prior to impl ementation of the change. 
  
GALDERMA LABORATORIES, L.P.  Page 76 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 25 BIBLIOGRAPHIC REFERENCES 
 
1.  Sherris DA, Otley CC, Bartley GB. Comp rehensive treatment of the aging face--
cutaneous and structural rejuvenati on. Mayo Clin Proc. 1998;73:139-146. 
 
2.  Amin SP, Phelps RG, Goldberg DJ. Meso therapy for facial skin rejuvenation: a 
clinical, histologic, and electron mi croscopic evaluation. Dermatol Surg. 
2006;32:1467-1472. 
 
3.  Little JW. Volumetric perceptions in midfacial aging with altered priorities 
for rejuvenation. Plast Re constr Surg. 2000;105:252–266. 
 
4.  Donofrio L, Weinkle S. The third dimension in facial rejuvenation:  a review. J Cosmet 
Dermatol. 2006;5:277-283. 
 
5.  American Academy of Facial Plastic Reconstructi ve Surgery 2006 Membership 
Survey: Trends in Facial Plastic Surgery, 2007. Available at:  
http://www.aafprs.org/wp-content/themes/aafprs/pdf/aafprsMedia2006.pdf  
 
6.  Bergeret-Galley C. Comparison of resorbable soft tissue fillers. Aesthetic Surg J 
2004;24:33-46. 
 
7.  Werschler WP, Weinkle S. Longevity of effects of injectable products for soft-
tissue augmentation. J Drugs Dermatol 2005;4:20-7. 
 
8.  Broder KW, Cohen SR. An overview of permanent and se mipermanent fillers. Plast 
Reconstr Surg  2006;118:7S-14S. 
 
9.  Silvers SL, Eviatar JA, Echavez MI, Pappas AL . Prospective, open-label, 18-month 
trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in  
patients with human immunodeficiency vi rus-associated lipoatrophy: one-year 
durability. Plast Recons tr Surg 2006;118:34S-45S. 
 
10. Sklar JA, White SM. Radiance FN: a new so ft tissue filler. Dermatol Surg 2004;30:764-
8; discussion 8. 
 
11. Burgess CM, Quiroga RM. Asse ssment of the safety and effi cacy of poly-L-lactic acid 
for the treatment of HIV-associated fa cial lipoatrophy. J Am Acad Dermatol 
2005;52:233-9. 
 
12. Mest DR, Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with 
HIV-associated lipoatrophy: the US ex perience. Dermatol Surg 2006;32:1336-45. 
 
13. Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of 
poly-L- lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 
2006;7:181-5. 
 
14. Valantin MA, Aubron-O livier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, et al. 
Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected 
patients:  results of the open-lab el study VEGA. Aids 2003;17:2471-7. 
 
15. American Society of Anesthesiologists (A SA). ASA Physical Status Classification 
System. Available at:  http://asahq.org/resources/clinical-information/asa-physical-status-
classification-system . 
 
GALDERMA LABORATORIES, L.P.  Page 77 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 16. Wrinkle Assessment Scale – Validation Study Dermik DL 6049 Summary of Statistical 
Analysis, Methodology and Resu lts (9/30/03). Data on file.  
 
17. Lemperle G, Holmes R, Cohen S, Lemperle S A Classification  of Facial Wrinkles. Plast  
Reconstr Surg 2001;108: 1735-1750.  
 
18. Fitzpatrick TB. The validity and practicality of sun-reactive skin Types I through 
VI [editorial]. Arch DermatoL 1988;124 (6):869-871.  
  
GALDERMA LABORATORIES, L.P.  Page 78 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 26  APPENDICES  
  
GALDERMA LABORATORIES, L.P.  Page 79 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 APPENDIX I – FITZPATRICK SKIN TYPE 
 
 
TYPE I: Pale white skin color that burns easily, strongly; never tans 
 
TYPE II: White skin color that burns easily; tans minimally with difficulty 
 
TYPE III: White skin color that burns moderately; tans moderately, and uniformly 
 
TYPE IV: Beige or lightly tanned skin color th at burns minimally; trans easily, 
and moderately 
 
TYPE V: Moderate brown or tanned skin color that rarely burns; tans profusely (dark 
brown) 
 
TYPE VI: Dark brown or black skin color that  never burns; tans profusely (deep 
brown or black) 
 
 
 
 
From: Fitzpatrick TB. The validity and practicalit y of sun-reactive skin Types I through 
VI [editorial]. Arch Dermatol. 1988;124(6):869-871.  
  
GALDERMA LABORATORIES, L.P.  Page 80 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 
APPENDIX II - NASOLABIAL FOLD WRINKLE ASSESSMENT SCALE 
  
0 
No Wrinkles 
PPD
GALDERMA LABORATORIES, L.P.  Page 81 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 APPENDIX III – ASSESSMENT SCALE FOR OTHER FACIAL 
WRINKLES 
 
 
0 = No  
Wrinkles 
1 = Just perceptible wrinkle 
2 = Shallow wrinkles 
3 = Moderately deep wrinkle 4 = Deep wrinkle, well defined edges 
5 = Very deep wrinkle, redundant fold 
 
Used with permission of Gottfried Lemperle   
PPD
GALDERMA LABORATORIES, L.P.  Page 82 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
  
 
0 = No Wrinkles 
1 = Just perceptible wrinkle 
2 = Shallow wrinkles 
3 = Moderately deep wrinkle 4 = Deep wrinkle, well defined edges 
5 = Very deep wrinkle, redundant fold 
 
Used with permission of Gottfried Lemperle 
  
PPD
GALDERMA LABORATORIES, L.P.  Page 83 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 Chin Crease  
 
 
 
  
 
  
 
  
 
  
 
 
 
0 =No Wrinkles  
1 = Just perceptible wrinkle  
2 = Shallow wrinkles  
3 =Moderately deep wrinkle  
4 =Deep wrinkle, well defined edges  
5 =Very deep wrinkle, redundant fold 
      Used with permission  of Gottfried Lemperle    
PPD
GALDERMA LABORATORIES, L.P.  Page 84 of 84 
Protocol GLI.04.SPR.US10321 CONFIDENTIAL  
FINAL Protocol Amendment 1 - Version 24 April 2015 
This document contains confiden tial, proprietary information. 
 APPENDIX IV – AMERICAN SOCIETY OF  
ANESTHESIOLOGISTS’ PHYSICAL  STATUS CLASSIFICATION 
SYSTEM 
 
 
 
P1  
A normal healthy patient 
  
 
P2  
A patient with mild systemic disease 
  
 
P3  
A patient with severe systemic disease 
  
 
P4  
A patient with severe systemic disease that is a constant threat to life 
  
 
P5  
A moribund patient who is not expected to survive without the operation 
  
 
P6  
A declared brain-dead patient whose organs are being removed for donor purposes 
 
 
 
PPD
PPD
PPD